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Alpha-synuclein aggregation is a hallmark pathological feature of Parkinson’s disease, and 
as such, it is thought to be a contributing factor to the disease. In the past, our group identified 
several compounds (1-aminoindan, nicotine, caffeine) capable of interacting with alpha-synuclein. 
These compounds were combined into bifunctional agents, such that caffeine was linked to one of 
1-aminoindan, nicotine, or caffeine by a six-carbon chain. The nicotine and 1-aminoindan 
bifunctional agents were able to interact with alpha-synuclein in vitro and rescue cell growth in a 
yeast cell model overexpressing alpha-synuclein. However, the specifics of this protein-ligand 
interaction are unknown as alpha-synuclein is intrinsically disordered. To gain insight into possible 
binding regions on alpha-synuclein, we propose to use diazirine photoaffinity labelling to identify 
these sites. Our approach toward creating the diazirine probes was to link a four-carbon chain 
containing a diazirine to the amines of theophylline, nornicotine, and 1-aminoindan. We began by 
converting the ketone moiety of 4-hydroxy-2-butanone to a diazirine ring in three steps. The linker 
was then either tosylated or iodinated at the alcohol position. At this stage, the tosylated linker can 
be used to alkylate the N7-position of theophylline, and the iodinated linker can be used to alkylate 
the primary amine of 1-aminoindan, the secondary amine of nornicotine, or the bifunctional 
compounds to complete the synthesis of the diazirine probes. Isothermal titration calorimetry was 
used to determine all compounds binding affinity for alpha-synuclein; however, the methodology 
was unable to produce reliable binding data. Characterization of the diazirine probe’s activity 
toward alpha-synuclein aggregation was carried out using a Thioflavin T assay. The results from 
these studies were compared to the unlabelled compounds to determine the probe’s ability to inhibit 
alpha-synuclein aggregation relative to the original compounds. No direct anti-aggregation activity 
was observed for any diazirine-functionalized probes or unfunctionalized compounds. To 
investigate the binding interactions between alpha-synuclein and the photoaffinity probe, the probe 
was incubated with alpha-synuclein and irradiated with UVA for 30 minutes prior to trypsin 
digestion and analysis by electrospray mass spectrometry or tandem mass spectrometry. This final 
step resulted in labelling of alpha-synuclein by the caffeine-diazirine derivative at the glutamic acid 
28 and tyrosine 39 amino acid positions. Labelling was not observed for the 1-aminoindan, 
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 Parkinson’s disease is a common neurodegenerative disease characterized by two main 
pathological features.1 The aggregation of protein into intracytoplasmic inclusions known as Lewy 
pathology is one of these pathological features. While many proteins make up these inclusions, 
alpha-synuclein is their primary component. 2,3 
 Alpha-synuclein is an intrinsically disordered protein thought to have a role in vesicular 
trafficking and cell signalling.4,5 It is commonly divided into three main sections: the N-terminus, 
the non-amyloid-β component region, and the C-terminus.  However, it is prone to aggregation 
under certain conditions.6 This aggregation leads to cellular dysfunction such as the production of 
reactive oxygen species, mitochondrial dysfunction, and cell death.7 As such, alpha-synuclein has 
become a primary target for treatment development in Parkinson’s disease as Parkinson’s disease 
treatments are not curative to date.   
 Several chemicals (caffeine, nicotine, and 1-aminoindan) have demonstrated a somewhat 
weak ability to interact with alpha-synuclein in previous work.8,9 To improve their capacity to 
interact with the protein, they were linked in different combinations with a six-carbon chain to 
produce bifunctional agents.10 These agents were caffeine six-carbon linked caffeine, caffeine 
linked 1-aminoindan, and caffeine linked nicotine. Two of these compounds, caffeine linked 1-
aminoindan, and caffeine linked nicotine, were capable of rescuing yeast cell growth in a cell model 
with excess alpha-synuclein, indicating potential suitability to being Parkinson’s disease drug 
candidates. The way the new bifunctional agents interacted with alpha-synuclein was not well 
understood. 
 Therefore, this work will focus on improving this understanding through three steps. The 
first step is through the synthesis of diazirine photoaffinity labelling probes, which are molecular 
probes activated by light to covalently link to the nearest molecule.11 Second, the probes will be 
characterized using biological assays such as the Thioflavin T assay which detects alpha-synuclein 
aggregation.12 Finally, photoaffinity labelling probes will be used in labelling studies to identify 
the amino acids to which the drugs bind.  
1.2 Parkinson’s Disease 
Parkinson’s disease (PD) is the second most common neurodegenerative disease.13–15 In 
North America, the prevalence is estimated to be 572 per 100,000 people above 45 years of age.13 
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It is rare for people below the age of 50 to be affected by the disease.14,15 However, the prevalence 
of PD only increases with age, reaching an estimated 3 to 4% within the population of those who 
are 80 years of age or older.  
 PD is best known for its three cardinal symptoms: bradykinesia, rest tremor, and 
rigidity.1,14,16 Postural instability was considered a cardinal feature in the past but has since been 
removed as it is considered to occur later in the progression of the disease. 16,17 To classify someone 
as having parkinsonism, bradykinesia – the slowness of movement – is required as well as either 
one or both of the remaining symptoms. 1,14,16  Once parkinsonism has been identified, the 
remaining inclusion and exclusion criteria can be applied for a formal diagnosis of either clinically 
established PD or clinically probable PD (for a more comprehensive explanation of criteria see 
16).14,16 While the majority of PD symptoms appear to be motor related, non-motor symptoms are 
also part of the inclusion criteria. 1,14,16 Non-motor symptoms of PD include sleep disturbances (e.g. 
rapid eye movement sleep behaviour disorder), hyposomnia, autonomic dysfunction (e.g. 
constipation), and psychiatric dysfunction (e.g. depression), all of which can significantly impair 
one’s quality of life. 16  Recently, evidence suggests that certain non-motor symptoms, such as rapid 
eye movement sleep behaviour disorder and olfactory loss, are some of the first indicators of the 
prodromal stage of the disease.18–20  
To be diagnosed with PD, clinical diagnosis by a specialist during life is considered the 
gold standard. 16 Post-mortem, the diagnosis can be confirmed through pathological testing for the 
hallmark traits of PD, the first of which is the degeneration and death of dopaminergic cells in the 
substantia nigra pars compacta (SNpc).2,21,22 Neurodegeneration of dopaminergic neurons happens 
preferentially in the ventrolateral region of the SNpc, sparing the other regions.  Evidence suggests 
that cell death in this region results in the motor features of parkinsonism.2 The second hallmark 
of PD is Lewy pathology (LP). In general, LP is defined as intracellular inclusions predominantly 
composed of aggregated α-synuclein (AS) protein.1–3,14 However, the intracellular protein 
inclusions are also composed of approximately 90 other types of molecules.1 LP can be separated 
into two categories, Lewy bodies and Lewy neurites, both of which are primarily AS protein. 2,3 
Lewy bodies differ from Lewy neurites in that Lewy bodies are intracytoplasmic inclusions 
whereas Lewy neurites are found in neurites. Unfortunately, both pathological features of the 
disease are not completely selective markers of PD. 2 SNpc dopaminergic cell degeneration and LP 
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are seen in other neurodegenerative diseases. Some guidelines are detailed in the literature to aid 
in proper pathological identification of PD; however, they require validation.  
Given the primary pathological features, it should come as no surprise that many PD 
treatments are centered around dopamine. The first treatment for PD was levodopa, a dopamine 
precursor that functions by supplementing the brain with dopamine. 23 Levodopa continues to be 
the standard for PD treatment of motor symptoms to date. 24 Subsequently, additional treatments 
for motor symptoms have been developed which include dopamine agonists, catechol-o-
methyltransferase inhibitors, monoamine oxidase-b inhibitors, and surgical interventions. 24,25 
These treatments are generally dopamine-oriented, like levodopa. Treatments for PD non-motor 
symptoms exist as well. 26 They are generally not universal, rather they are targeted towards 
individual symptoms of the disease. None of these treatments, motor or non-motor, have been able 
to delay or cure the disease, indicating that the underlying cause for PD must lie elsewhere. 25  
In 1997, the first genetic mutation associated with PD was identified as an alanine to 
threonine substitution at the 53 position of AS protein in the SNCA gene. 27  This discovery was 
monumental as it was the first to implicate both a monogenic and AS cause for PD. In the years 
that followed, many other SNCA mutations, including whole locus multiplications, as well as other 
genetic loci aside from the SNCA gene were discovered that have a role in PD. 28,29 To date, over 
twenty genetic loci have been associated with PD as well as certain genetic risk factors. Most cases, 
however, are sporadic in nature and only a small percentage, roughly 5 to 10%, are familial. 28  
Regardless, the information garnered from such studies has led to the identification of 
potential PD treatment targets. Aside from AS, leucine rich repeat kinase 2, VPS35, and parkin 
RBR E3 ubiquitin ligase are among the most studied. 28  Proteins such as these are involved in 
vesicular trafficking, protein degradation, and protein transportation, which appear to be some of 
the overarching themes on the molecular level. Despite this, much is still uncertain as to how these 
definitively result in PD. However, much of the pathogenesis is suspected to rely on the protein 
alpha-synuclein.  
1.3 Alpha-Synuclein (AS) 
Alpha-synuclein is a 140 amino acid long protein weighing 14 460 Da. AS is known for 
existing in an intrinsically disordered state in solution and in the intracellular environment. 4,30 
However, there are conflicting reports that AS exists as a helically folded tetramer. 31  In reality, 
both conformations may exist in a dynamic equilibrium. Native AS will also transition into an 
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alpha-helical form when interacting with phospholipid bilayers, preferring acidic phospholipids to 
net neutral vesicles. 32 Unsurprisingly, it is abundant in the nervous system, but AS can also be 
found in other tissues, including red blood cells. 33,34  
AS is predominantly localized to the pre-synaptic terminals of neurons and synaptic 
vesicles due to its preference for surfaces with high curvature. 5,35 It appears to have a synaptic 
regulatory function. There are multiple claims of AS activity which include protein interactions, 
lipid interaction and modulation, chaperone activity, dopamine regulation, and many more. 36 Other 
than that, it is thought to have a role in the function of the mitochondria. 37 Ultimately, alpha-
synuclein’s physiological function is not completely understood despite years of study. 
Alpha-synuclein is divided into three sections (Figure 1.1): the N-terminal region, the non-
amyloid-β component (NAC) region, and the C-terminal region. The N-terminal region ranges 
from residues 1 to 60. Interestingly, most of the known genetic mutations in the SNCA gene reside 
in this region: A30P, E46K, H50Q, G51D, A53E, and A53T. 28  The NAC region runs from residues 
61 to 95. This region was first discovered in the study of Alzheimer’s disease and amyloid 
deposition, hence its name. 38 It is a hydrophobic region thought to be highly involved in misfolding 
and aggregation of protein.  Both the N-terminal region and NAC region confer AS the ability to 
bind charged lipids due to the seven 11-mer repeats and consensus sequence which makes it form 
a three-turn, amphipathic alpha helix. 35 Finally, there is the C-terminal region from residues 96 
onward. The C-terminal region is acidic and largely unstructured even when bound to micelles. 39  
Aggregation regulation is thought to occur because of this region. 40 Finally, a chaperone-mediated 
autophagy sequence from residues 95 to 99 assists with protein degradation. 41  
 
Figure 1.1 AS protein: all three regions and the amino acid residues which define them. Red 
(left) is the N-terminal region which goes from residues 1 to 60. Blue (middle) is the NAC region 
from residues 61 to 95. Light green (right) represents the C-terminus from residues 96 to 140.  
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Rather than being in disordered or alpha-helical form, AS can also form aggregates with 
beta-sheet structures like other amyloid diseases. 6  (Figure 1.2). In this first step of the aggregation 
process, the free, monomer AS forms soluble oligomers. 42  Evidence suggests that even at this 
stage AS oligomers can disrupt cell functions. 43–45  These oligomers then go on to form insoluble 
amyloid fibrils which will become Lewy pathology. 42  Lewy pathology and AS fibrils are thought 
to result in reactive oxygen species, mitochondrial dysfunction, and degeneration of dopaminergic 
neurons. 7   
 
Figure 1.2 Illustration of AS progression into fibrils. Free AS first transitions to oligomers and 
then into fibrils.  
There are many factors influencing alpha-synuclein’s aggregation which include, but are 
not limited to, the following. Phosphorylation of serine-129 is thought to contribute to aggregation, 
possibly by increasing the rate of aggregation. 46,47  As previously noted, mutations in the SNCA 
gene are linked to PD. 28 In vitro evidence suggests these mutations play a role in the rate of 
aggregation as well as elongation. 48 Lipid vesicles and the solution pH were also contributing 
factors to aggregation. As with the current understanding of alpha-synuclein’s physiological 
function, the precise cause and mechanism of alpha-synucleinopathy initiation are not yet 
completely understood.  
The most concerning property of AS is its prion-like infectiousness. Seeded aggregation is 
the mechanism by which this is thought to occur. Through seeded aggregation, fibril fragments 
leave infected cells and initiate fibrillization in uninfected cells. 49  Evidence shows that AS seeds 
can act as fibrillization sites for free AS. 48,50 Several studies have documented support for cell to 
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cell transmission of AS aggregates and Lewy pathology as well. This was first confirmed when 
neural tissue grafts demonstrated Lewy pathology post-mortem following transplantation into PD 
patients. 51  In mouse models, AS pathology was found in the central nervous system following 
intramuscular injection of AS seeds, implying retrograde transport and propagation of disease. 52 
Further work with the same model demonstrated this transmission occurs in other peripheral sites. 
53  
To study the formation of these AS aggregates in vitro, the gold standard approach for fibril 
detection is the thioflavin T (ThT) assay. Thioflavin T specifically interacts with amyloid fibrils 
and protofibrils in vitro due to their beta sheet character and does not interact with other unfolded, 
folded, or oligomeric proteins. 12  ThT may be performed in cells; however, it is less specific as 
ThT may interact with other cellular components. 54   
To perform the assay in vitro, monomeric proteins are solubilized in buffer and allowed to 
aggregate although specific experimental conditions vary. 12 It is most desirable to have monomeric 
proteins present at the start of the assay and not oligomeric proteins as this will affect growth rates. 
Adding ThT will allow visualization of aggregation via a blue shift in fluorescence emission from 
510 nm to 480 nm. 12,55  Excitation of ThT occurs around a 450 nm maximum. 55 More fluorescence 
from the solution implies more aggregation; thus, ThT may be used to observe the effects small 
molecules may have on protein aggregates.   
Two experimental protocols are typically used to measure fibril formation. In the first, ThT 
is present in the protein mixture and measurements are taken over time. 12  Less protein is required 
in these assays, making kinetics-based assays more affordable. This method receives criticism from 
the fact that ThT may interfere with fibril formation and small molecule binding. 56  The second 
protocol does not have ThT present, and samples are extracted from the mixture which are then 
read with ThT. 12 More protein is necessary in these experiments, but the aggregation mixture is 
simpler.  
1.4 Other AS diseases 
PD is not the only disease afflicted by the aggregation of AS. Dementia with Lewy bodies 
(DLB), Parkinson’s disease dementia (PDD), and multiple system atrophy (MSA) also exhibit AS 
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pathology. Along with PD, these illnesses are termed alpha-synucleinopathies because they share 
AS proteinaceous inclusions.  
DLB and PDD share a considerable amount of overlap. Both diseases consist of fluctuating 
cognition, cognitive impairment, rapid eye movement sleep behaviour disorder, parkinsonism, and 
visual hallucinations. 57–59  However, DLB and PDD are differentiated temporally. 57 DLB may 
present first as dementia followed by parkinsonism, or dementia and PD symptoms may appear 
concurrently. For PDD on the other hand, the PD precedes the development of dementia by twelve 
months, making PDD a subtype of PD. Due to their similarities, it is debated as to whether they are 
distinct diseases and should be qualified as such. 57,58  Pathologically, there is not a distinction 
based on current international pathological staging systems. 59   
MSA on the other hand is quite different from PDD and DLB. MSA presents with 
progressive autonomic failure as well as parkinsonian, pyramidal, and cerebellar features. 60,61 Like 
DLB and PD, MSA also has proteinaceous AS inclusions. However, they are oligodendroglial 
cytoplasmic inclusions called Papp-Lantos bodies, as opposed to PD and DLB where AS 
accumulation is seen in neurons.   
All three diseases exhibit similarities with respect to the presence of alpha-synuclein. PD 
likely receives more attention due to its prevalence as compared to these diseases, but it is possible 
these three diseases would benefit from a better understanding of AS. Also, treatments targeted 
toward AS may be beneficial for the broader category of alpha-synucleinopathies.  
1.5 Previous Work  
A common practice in the field of biochemistry is to turn toward epidemiological studies 
for potential drug candidates. Reviewing such literature in the field of PD and AS indicated to Dr. 
Lee that there were three likely drug candidates for PD treatment. 8,9  
Genetics are not the only contributing factor to Parkinson’s disease. Environmental factors 
influence one’s likelihood of developing PD as well. Studies have found cigarette smoking to be 
inversely related to the incidence of PD, which implies that the primary constituent – nicotine – 
may act as the active ingredient. 62–64  Caffeine, another natural product, also has an inverse 
relationship to the incidence of PD. 65,66  Finally, 1-aminoindan, a metabolite of rasagiline, was 
selected for further study as there was evidence to suggest that it may have neuroprotective effects. 




Figure 1.3 Potential drug hits for PD therapies. Left to right: caffeine, nicotine, 1-aminoindan. 
 Given the evidence from the aforementioned studies, caffeine, nicotine, and 1-aminoindan 
(Figure 1.3) were tested for the ability to interact with AS. 8,9 These three molecules possessed the 
ability to interact with AS as evidenced by nanopore analysis, circular dichroism, nuclear magnetic 
resonance (NMR), and/or isothermal titration calorimetry (ITC). Within these studies, nicotine was 
studied in more detail. Nanopore and NMR suggested that nicotine preferentially interacted with 
the C- and N-terminal regions of AS. 8  The interaction is thought to result in AS adopting a loop 
conformation (Figure 1.4), as ITC data suggests a 1:1 ratio of drug to protein.    
 
Figure 1.4 Hypothesized mechanism of interaction for neuroprotective compounds. 
Given the ability of these molecules to interact with AS, it was hypothesized that by 
combining two of these molecules into one larger molecule that two possible effects could be 
observed. First, the strength of the interaction between the combined molecule and the protein will 
be stronger than that of the individual molecules. Second, the bifunctional compounds would have 
increased activity because they bring two active components in proximity, and the second binding 
event could follow the first binding event more easily. 
 Therefore, work was carried out to synthesize a variety of bifunctional agents which linked 
caffeine to 1-aminoindan, caffeine, or nicotine with a six carbon chain (Figure 1.5). 10 When 
assessed for their ability to bind to AS, there was little improvement in the strength of interaction 
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as one might have expected given the previous hypothesis. Notably, caffeine six carbon linked 
caffeine (C8-6-C8) was an exception to this finding as its Kd was far greater than caffeine, its 
monomer. To evaluate the second half of the hypothesis, the compounds were tested in a yeast cell 
model overexpressing AS. Two compounds, caffeine linked 1-aminoindan (C8-6-I) and caffeine 
linked nicotine (C8-6-N), were able to rescue cell growth more effectively than the monomer 
compounds, other bifunctional compounds, or combinations of monomer compounds. This 
evidence could suggest that C8-6-I and C8-6-N interact with AS to rescue cell growth, but given 
their lower binding constants, other cellular mechanisms may help rescue cell growth as well.  
Regardless, additional study and experimentation could offer more insight toward solving 
the discrepancy between ITC results and yeast cell results. It is not understood where the 
bifunctional and monomer compounds interact with AS protein. As the different regions of AS are 
responsible for different effects on aggregation, this information could guide drug development for 
PD as well as aid in understanding AS aggregation itself.  For intrinsically disordered proteins, 
crystal structures may be ideal to visualize the protein-ligand interaction, but to date have been 
unobtainable for AS. Thus, there exists the need to employ alternative methods to understand how 




Figure 1.5 Bifunctional compounds of interest in the present study. Compounds are as follows: 
C8-6-N (top), C8-6-I (middle), C8-6-C8 (bottom).  
1.6 Photoaffinity Labelling 
Photoaffinity labelling (PAL) is a chemical biology technique that allows insight into the 
interaction of a probe and a biomolecule. 69  To perform PAL, a molecular probe is first synthesized 
which contains both the photophore and the structural motif of interest. The structural motif’s 
purpose is to mimic the ligand of interest, whereas the photophore’s purpose is to be activated by 
light and form a covalent bond where the motif interacts.  This molecular probe is then incubated 
in the target system and allowed to interact with biomolecules in the location it prefers (Figure 1.6). 
Photoirradiation in the ultraviolet (UV) range activates the photophore, forming a covalent bond 
between the probe and its target. This probe-biomolecule complex is then analyzed, and 
conclusions are drawn regarding the probe’s ability to interact. PAL can be applied to study protein-
protein interactions. 11 However, most work in the field focuses on biomolecule-ligand interactions.  
 
Figure 1.6 Illustration of the process of photoaffinity labelling. The green circle represents the 
structural motif that is attached to a photophore (green triangle) used for labelling. Once incubated 
with the protein (blue square) and UV light, the protein-probe complex forms via the formation of 
a covalent bond due to activation of the photophore.  
PAL is used for two major applications. The first is in situ which provides the probe 
exposure to a wide range of potential targets. Overall, in situ labelling is particularly useful in drug 
discovery for identifying a more complete range of targets a drug may have in a cell system. 
Depending upon the experiment, the probe will have another functional group, referred to as a tag. 
There are many potential tags that could be introduced to the probe which include, but are not 
limited to, biotin, isotopes, fluorophores, or reactive groups (e.g. a terminal alkyne). 69–71  Biotin is 
used in studies as it can be isolated with affinity chromatography, allowing labelled biomolecules 
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to be isolated. Isotopes and fluorophores are used as tags for visualization of labelled proteins or 
proteins subunits. Reactive groups are used as tags because they are smaller and modify the 
chemical structure of the probe less, allowing cell permeation. Also, they can be chemically linked 
to other tags in subsequent steps, allowing for the benefits of different tags while minimizing 
changes to the probe’s structure during labelling.  
The second application of PAL is far simpler. In this case, PAL may be performed in vitro. 
This is generally completed for the purpose of binding site identification. In vitro PAL is ideal for 
providing insight into the binding sites of a molecule on a protein, identification of allosteric sites, 
and potentially even identification of protein conformation.  
Following labelling, the probe-biomolecule complex must be analyzed. High performance 
liquid chromatography (HPLC) coupled to mass spectrometry (MS) is frequently used for analysis 
of the labelled biomolecules. 72   HPLC separates the components in solution and MS identifies the 
number of probes attached to the protein. Enzymatic digestion is then performed following the 
PAL procedure to break proteins down into shorter peptide sequences. Tandem mass spectrometry 
(MS/MS) following HPLC separation of the peptide digest allows for more precise identification 
of the labelling sites. Under ideal conditions, MS/MS can fragment the labelled peptides such that 
the modified amino acid can be determined. HPLC-MS or HPLC-MS/MS can be applied for the 
identification of biomolecules from in situ experiments as well, but additional purification is 
typically employed before analysis. The cells are lysed, tagged, purified with affinity 
chromatography, and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
before HPLC or enzymatic digestion. However, advances in proteomics are making purification 
before analysis less of a requirement. 73  
When designing a PAL experiment, probe design requires consideration. First, the 
photophore should be stable to the system conditions. 70,72,74 Decomposition of the photophore in 
the system may result in a false negative. The photophore should also be activated by light in a 
range that does not negatively affect the system. As well, the by-products of probe activation should 
not negatively affect the system. Essentially, negatively affecting the system may impact the results 
in a way that may not be an accurate representation of probe binding. Next, the probe should be as 
similar as possible to the molecule it is trying to mimic. Biochemical assays or in silico testing can 
be performed to evaluate the similarity between the probe and the molecule. Finally, the bond 
between the probe and target must be stable enough that analysis can be completed without being 
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concerned about decomposition. Given these criteria, benzophenones, aryl azides, and diazirines 
are the most applied photophores in PAL literature. 
There are many advantages for the use of benzophenones in PAL. Benzophenones are 
activated by UVA light in the range of 350-365 nm, a long enough range that biomolecules should 
not be affected. Irradiation causes the benzophenone to convert to a triplet diradical state (Figure 
1.7). The activated photophore can exist in this state for up to 120 μs before relaxing to ground 
state if it remains unreacted. 69 The triplet diradical reacts in a long understood, two-step 
mechanism, hydrogen abstraction followed by recombination. The active species prefers to react 
with O-H and C-H bonds, meaning it can react with all amino acids. The active state is essentially 
inert to water because the reacted product will convert back to the ketone via dehydration shortly 
after reacting with water. 69,71  Synthesis of the benzophenone is also easy as starting materials are 
commercially available. 
Certain drawbacks exist as well. Benzophenones are relatively large and bulky 
photophores, as such they may not be the most appropriate for all PAL studies because of their 
impact on probe activity. 69,71,72  Furthermore, longer irradiation times (more than 30 minutes) are 
required for benzophenones which may lead to substantial non-specific binding. Finally, while able 
to react with all amino acids, certain locations are preferred.              
 
Figure 1.7 Benzophenone activation scheme. Benzophenone (left) is converted into diradical 
(right).  
 Aryl azides are the second of the three commonly used photophores in PAL. They are 
activated by relatively short range light (250-350 nm). 72  The azide becomes a singlet nitrene once 
it is activated (Figure 1.8), losing inert N2 gas.
 69   The singlet nitrene can relax to a less energetic 
triplet state if it remains unreacted during its 0.1 ms lifetime. Both species will insert into C-H 
bonds through different, long established mechanisms. The singlet species reacts via insertion, and 
the triplet species reacts via hydrogen abstraction followed by recombination. Ultimately, the 
products from both the singlet and triplet species are the same. The major benefits to using aryl 
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azides in PAL are their size and the ease of synthesis. 69,72  Beginning from their respective amine, 
azides can be synthesized in either one or two steps. 75,76 The loss of nitrogen gas during activation 
can also be considered relatively beneficial as nitrogen gas should not affect biological systems.  
 
Figure 1.8 Aryl azide activation scheme. Aryl azide depicted on the left and nitrene on the right. 
 The major drawback of aryl azides in PAL is their activation. Activation occurs in a range 
that is harmful toward biomolecules. 69,72  While the loss of nitrogen gas in their activation should 
not impact biological systems, the wavelength of light required for activation renders this benefit 
questionable. The final major disadvantage of aryl azides is their propensity to undergo side 
reactions. 69  The singlet species can be converted to benzazirines and dehydroazepines, which will 
react with nucleophiles. The triplet species can be oxidized to the nitro species. The azide itself can 
also be reduced back to the amine form. All these reactions can result in difficulties achieving high 
labelling yields.  
 The third and final of the common PAL photophores are diazirines. Diazirines are small 
photophores that are activated by light in the 350 to 380 nm UVA range. 69,72 Once activated, the 
diazirine loses nitrogen gas and becomes a singlet carbene (Figure 1.9) with a half-life in the 
nanosecond range. Such a brief half-life is excellent for reducing non-specific labelling of 
biomolecules. This carbene species can insert into O-H, C-H, and N-H bonds. The mechanisms of 
diazirine reactions have been understood for many years. It can convert into a triplet carbene state 
capable of reacting with C-H bonds though a diradical mechanism. When activated by light, the 
diazirine may convert into a diazoisomer instead of the singlet carbene. However, the diazoisomer 
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is still capable of converting to the singlet carbene state. Diazirines are also stable to a wide range 
of conditions, which is beneficial during both the synthesis and labelling.  
 
Figure 1.9 Activation of aryl diazirine (left) to a carbene (right). 
 Due to the short half-life, quenching of the carbene by solvent frequently occurs, resulting 
in lower labelling yields. 69 Another aspect affecting labelling yields is the conversion of the 
diazoisomer to the singlet carbene state. The conversion takes a long time which can again lead to 
difficulties with labelling efficiency and potentially non-specific labelling. The triplet state carbene 
may be oxidized, again limiting labelling. As well, diazirines are typically divided into two groups: 
alkyl diazirines and aryl diazirines, each with its own flaws. In the case of alkyl diazirines, a hydride 
shift can occur converting the carbene to a double bond and further reducing labelling yields. 
Finally, synthesis of diazirines is relatively difficult, particularly for aryl diazirines. 
 Clearly, there are benefits and drawbacks to all the most used photoactivatable groups in 
PAL. Comparing benzophenones, aryl azides, and diazirines solely based upon such information 
may be misleading as labelling efficiency is also dependant upon the target. 77 Comparing 
photophores based upon in silico modelling may be an appropriate approach toward selecting the 
optimal photophore with which to modify the drug. However, AS is the target protein and most of 
the studies have been performed with unfibrillated, free in solution AS. 8–10,78  Although examples 
in the Protein Data Bank (PDB) report crystal structures of AS fibrils or AS segments bound to 
other peptides, to date, there is no structure in the PDB of unbound, monomeric AS which would 
be sufficient for in silico testing of free AS. Therefore, the selection of photophore must be based 
upon what is synthetically possible. Caffeine is the most troublesome of all the compounds as it is 
small and limited in its ability to be modified with a photophore. For this reason, the addition of a 
short alkyl diazirine linker to the N7 position of theophylline was chosen. This linker will be far 
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smaller than benzophenones, aryl azides, or aryl diazirines. For consistency, this linker will be used 
for all other compounds. 
PAL of AS has not been published frequently in literature. To date, there is only one study 
that has performed PAL on AS which was published in 2018. 79 Several major differences exist 
between the current work and what was published. Most notably, labelling was performed on pre-
fibrillated AS using aryl azide photophores on completely different drugs. The success of the 2018 
study suggests PAL may be viable for unfibrillated AS while the limited number of studies suggest 
work in the area is still novel.    
1.7 Diazirines 
 To perform this study, both the monomer compounds and bifunctional agents must have 
diazirines. Considering the ways diazirines can be incorporated onto these molecules, creating a 
diazirine linker that could be used to alkylate nitrogen atoms is the simplest course of action. Given 
the size of aryl diazirines, it would be better to use a small alkyl diazirine chain. Ideally, this chain 
would be as small as possible (e.g. hydroxyacetone could be used as a starting material). However, 
synthesis of a diazirine from this compound in our lab was unsuccessful (M. Pirlot, personal 
communication). Therefore, synthesis of a four-carbon chain diazirine linker was chosen. Many 
researchers were able to successfully convert 4-hydroxy-2-butanone into 3-(2-hydroxyethyl)-3-
methyl-3H-diazirine in the literature. Often, the hydroxyl group is subsequently converted to a 
different leaving group. The resulting compound is used in alkylation reactions, just as desired for 
this work. 
Synthesis of 3-(2-hydroxyethyl)-3-methyl-3H-diazirine is completed in three steps (Figure 
1.10). The most common synthetic strategy to produce this diazirine linker is as follows. 80–85 First, 
liquid ammonia is condensed into a flask containing 4-hydroxy-2-butanone and allowed to react 
for approximately 5 hours, sometimes refluxing at around -30 °C. This results in conversion of the 
ketone to an imine which is then transformed into a diaziridine with the addition of hydroxylamine-
O-sulfonic acid in methanol. The length of step two varies considerably in the literature; typically, 
it occurs overnight. The reaction is brought to room temperature during this time and followed by 
filtration and concentration in the morning. The diaziridine is converted finally to a diazirine in the 
third step. Iodine is added to the compound and triethylamine on ice until the colour of iodine 
persists. This step typically takes two hours to complete, but again there is a wide range in the 
literature from ten minutes to five hours. The reaction is extracted and purified by column 
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chromatography. The overall yield for the conversion of 4-hydroxy-2-butanone to 3-(2-
hydroxyethyl)-3-methyl-3H-diazirine in the literature ranges from 30-51%. 80–84   However, one 
patent reported a 3% yield for this reaction. 85   
 
Figure 1.10 Synthetic scheme of diazirine linker depicting a typical synthetic route. 
 Several alternatives to this pathway exist. One alternative is the replacement of liquid 
ammonia in the first step of Figure 1.10 with ammonia in methanol. 86,87  This substitution may be 
particularly useful as ammonia in methanol can be purchased commercially in small quantities. If 
large scale synthesis is not the goal, this may be more ideal. However, the yield appears to suffer 
as a result of this alteration, excluding the patent which reports a 3% yield. 85  When everything in 
the reaction is kept consistent, literature yields were 20% and 28%. 86,87   
 Other studies have focused more on the reagents used in the conversion of the diaziridine 
to a diazirine. One study reports the use of tBuOK to perform the final transformation. 88  The yield 
for this reaction was 62% conversion from the ketone to the diazirine, 11% higher than the next 
best yield. At first glance, this appears to be an effective way to increase the yield from a relatively 
low yielding reaction. However, there were several major changes to the standard protocol for this 
reaction that do not allow for a direct comparison. Most notably, the reaction makes use of a sealed 
metal tube capable of withstanding high pressures (10 MPa). The study does not control for the use 
of the sealed tube. Therefore, it is possible that the tube may have the biggest impact in the first or 
second step, and the use of tBuOK is not the determining factor for the observed increase. 
Regardless, this was one of the higher yielding reactions for this compound.  
 Another study by the same group compared the use of different bases for the 
dehydrogenation of the diaziridine. 89  This study made use of the same one-pot, sealed tube 
synthesis as the previous study to test ten different bases that are typically cheaper and easier to 
handle than tBuOK. All bases were compared using levulinic acid, and the highest yielding base 
(KOH) was then applied to create diazirines of several other compounds. It is possible the most 
effective base for levulinic acid may not be the same for all other compounds, but the study 
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demonstrated an increased yield for 3-(2-hydroxyethyl)-3-methyl-3H-diazirine (75% yield) as 
compared to the tBuOK reaction. 88,89   To the best of my knowledge, this is the highest yield for 
this diazirine compound.  
 For the general category of alkyl diazirine synthesis, there is another common approach to 
diaziridine transformation into diazirines. Silver oxide (Ag2O) may be used to oxidize diaziridines.
 
90,91  However, the process tends to be low yielding and require additional filtration due to the silver 
salts. 
 Finally, there is one last interesting alternative for the oxidation of diaziridines: NaClO. 
Sodium hypochlorite, or bleach, has been used to obtain high yields for the oxidation of diaziridines 
to diazirines on certain molecules. 92 A 6% w/v solution of bleach was used to convert 
adamantanone diaziridine to adamantanone diazirine (Figure 1.11) resulting in a 99% yield in this 
step. The article hints at the synthesis of other alkyl diazirines being less than favourable, but the 
comment lacks clarity surrounding whether or not 6% bleach was used in the synthesis of other 
alkyl diazirines. Given the cost-effectiveness and availability of bleach, this may be the best 
departure point for the synthesis of diazirines.    
 





1. The diazirine-functionalized probes will interact with AS the same way that the drugs 
from which they are derived interact with AS. 
2. The diazirine-functionalized probes will preferentially label the N- and C- terminal 
regions of AS. 
1.9 Objectives 
a. To synthesize photoaffinity labelling probes of all molecules being studied. 
This study will focus on both the monomer and bifunctional compounds. Caffeine, 1-
aminoindan, nicotine, C8-6-C8, C8-6-I, and C8-6-N diazirine probes will be synthesized.  
b. To characterize the activity and binding affinity of the probes and compare them 
to the original drugs.  
All diazirine labelled probes and the drugs upon which they are based will be subjected 
to isothermal titration calorimetry to determine binding affinity. The same compounds 
AS aggregation inhibition activity will be determined by Thioflavin T assays. The data 
from each of the probes will be compared to their respective drug to determine the 
impact of the linker. 
c. To perform photoaffinity labelling and mass spectrometric proteomics with the 
characterized probes. 
Photoaffinity labelling will be performed using a simple in vitro design. This will be 
followed by tryptic digestion of the protein and HPLC-MS or MS/MS. Digestion, mass 
spectrometry, as well as data analysis and validation will be performed by collaborators. 





2.1 Ethical Considerations 
This project does not involve either animals or humans. Therefore, no ethical approval is 
required. 
2.2 Reagents  
 All chemicals were obtained commercially, mainly from either Sigma-Aldrich or Alfa 
Aesar. Alpha -synuclein was purchased from rPeptide. 
2.3 Compound Synthesis 
2.3.1 3-(2-hydroxyethyl)-3-methyl-3H-diazirine 
 
 4-hydroxy-2-butanone (1 eq, 5.67 mmol) was put under nitrogen and on ice.  The ketone 
was dissolved in 7N ammonia in methanol (5.67 mL) and reacted for 3.5 hours. Hydroxylamine-
O-sulfonic acid (1.1 eq, 6.24 mmol) dissolved in methanol was added to the mixture, allowing the 
reaction to come to room temperature overnight. The precipitate was filtered off and the filtrate 
was concentrated in vacuo, resulting in a thick, yellow oil. The oil was returned to ice after drying. 
A minimal amount of ice was added to the flask, followed by diethyl ether (15 mL) and 6% bleach 
(NaOCl, 35 mL). The resulting solution was stirred for 1.5 hours, adding ice chips throughout. The 
reaction mixture was then extracted with 3 x 20 mL diethyl ether. The organic layers were 
combined and dried over MgSO4. The mixture was then concentrated in vacuo at 22 °C and 370 
mbar without further purification, resulting in a yellow, watery oil (51% crude yield in three steps, 
0.297 g). 1H NMR (CDCl3, 500 MHz, 22 °C): δ 3.53 (t, J = 6.3 Hz, 2H), 1.64 (t, J = 6.3 Hz, 2H), 







2.3.2 2-(3-methyl-3H-diaziren-3-yl)ethyl 4-methylbenzenesulfonate 
 
3-(2-hydroxyethyl)-3-methyl-3H-diazirine (1 eq, 0.718 mmol) was dissolved in anhydrous 
dichloromethane under nitrogen on an ice bath. Triethylamine (2 eq, 1.437 mmol) was added and 
stirred for ten minutes. p-Toluenesulfonyl chloride (1.4 eq, 1.006 mmol) was dissolved in 
anhydrous dichloromethane and then added dropwise to the reaction. The solution was stirred 
overnight, allowing the reaction to come to room temperature. Pyridine (2 mL) was added to the 
mixture. After ten minutes, the reaction mixture was washed with 20 mL 1 M HCl, then 20 mL 
saturated sodium bicarbonate, and finally, 20 mL brine. The organic phase was dried over MgSO4, 
filtered, and dried in vacuo. Purification by column chromatography (1:1 DCM:Hexanes) yielded 
a pale yellow oil (75% yield, 0.136 g). 1H NMR (CDCl3, 500 MHz, 22 °C): δ 7.81 (d, J = 8.3 Hz, 
2H), 7.37 (d, J = 8.0 Hz, 2H), 3.95 (t, J = 6.4 Hz, 2H), 2.54 (s, 3H), 1.67 (t, J = 6.4 Hz, 2H), 1.00 
(s, 3H). 
2.3.3 Caffeine diazirine 
 
Theophylline (1.5 eq, 1.07 mmol) and K2CO3 (10.5 eq, 7.54 mmol) were placed under 
nitrogen and dissolved in DMSO. 2-(3-methyl-3H-diaziren-3-yl)ethyl 4-methylbenzenesulfonate 
(1 eq, 0.72 mmol) was dissolved in anhydrous tetrahydrofuran and added dropwise to the 
theophylline solution. The mixture was heated to 50 °C and reacted overnight. The reaction was 
poured into 30 mL water and extracted with 3 x 40 mL DCM. The organic layers were combined 
and washed with 3 x 25 mL water. Finally, the organic layers were dried (MgSO4) and concentrated 
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in vacuo.  Purification by column chromatography (EtOAc: Hexanes 8:2) yielded a lightly yellow 
oil (49%, 0.086 g). 1H NMR (CDCl3, 500 MHz, 22 °C): δ 7.65 (s, 1H), 4.21 (t, J = 7.0 Hz, 2H), 
3.61 (s, 3H), 3.42 (s, 3H), 1.97 (t, J = 7.0 Hz, 2H), 1.00 (s, 3H). 13C NMR (CDCl3, 500 MHz, 22 
°C): δ 155.12, 151.83, 149.42, 141.14, 106.88, 42.29, 36.01, 30.03, 28.23, 23.81, 20.03. ESI-MS: 
m/z 263.1 ([M+H]+).  
2.3.4 3-(2-iodo-ethyl)-3-methyl-3H-diazirine 
 
Triphenylphosphine (1.2 eq, 1.19 mmol) and imidazole (2.4 eq, 2.38 mmol) were placed 
under nitrogen at 0 °C and dissolved in anhydrous DCM. I2 (1.2 eq, 1.19 mmol) was then added to 
the flask. 3-(2-hydroxyethyl)-3-methyl-3H-diazirine (1 eq, 0.99 mmol) was dissolved in anhydrous 
DCM and added dropwise to the mixture. The reaction was stirred for 4 hours, allowing it to come 
to room temperature. Water (6 mL) was added to the mixture before extracting with 2 x 10 mL 
DCM. The organic phases were combined and dried (MgSO4) before concentration in vacuo. 
Column chromatography (10:1 Hexanes:Et2O) resulted in a lightly yellow oil (46% yield, 0.098 
g). 1H NMR (CDCl3, 500 MHz, 22 °C): δ 2.95 (t, J = 7.6 Hz, 2H), 2.02 (t, J = 7.6 Hz, 2H), 1.08 (s, 
3H). 
2.3.5 1-aminoindan diazirine 
 
1-aminoindan (1.5 eq, 0.698 mmol) was dissolved in anhydrous acetonitrile under nitrogen. 
DIPEA (3 eq, 1.395 mmol) was added to the mixture and stirred for 1 hour. 3-(2-iodo-ethyl)-3-
methyl-3H-diazirine (1 eq, 0.465 mmol) was dissolved in anhydrous acetonitrile then slowly added 
to the reaction mixture. The solution was heated to 45 °C and stirred overnight. Water (10 mL) was 
added and the reaction was extracted with 3 x 20 mL DCM. The organic layers were combined and 
dried over MgSO4 before drying in vacuo. The crude product was purified using column 
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chromatography (EtOAc:Hexanes 2:8) resulting in a yellow oil (42 %, 0.108 g). 1H NMR (CDCl3, 
500 MHz, 22 °C): δ 7.34 (bt, J = 8.3 Hz, 1H), 7.24-7.18 (m, 3H), 4.18 (t, J = 6.6 Hz, 1H), 3.02-
2.96 (m, 1H), 2.81 (p, J = 15.9, 15.6 Hz, 1H), 2.54 (dt, J = 13.9, 7.3 Hz,  2H), 2.40-2.34 (m, 1H), 
1.82-1.75 (m, 1H) , 1.68-1.58 (m, 2H), 1.26 (bs, 0.5H), 1.04 (s, 3H). 13C NMR (CDCl3, 500 MHz, 
22 °C): δ 145.06, 143.75, 127.67, 126.47, 124.97, 124.29, 63.43, 42.05, 34.94, 33.53, 30.54, 25.00, 
20.40. ESI-MS: m/z 215.9 ([M+H]+). 
2.3.6 Nicotine diazirine 
 
(+/-)-nornicotine (1.1 eq, 0.75 mmol) was placed under nitrogen and dissolved in anhydrous 
acetonitrile. DIPEA (1.5 eq, 1.02 mmol) was added to the (+/-)-nornicotine solution and allowed 
to stir for 1 hour before adding 3-(2-iodo-ethyl)-3-methyl-3H-diazirine (1 eq, 0.68 mmol) also 
dissolved in anhydrous acetonitrile. The mixture was heated to 60 °C and stirred overnight. The 
reaction was cooled to room temperature before adding 30 mL saturated NaHCO3 and extracting 3 
x 40 mL DCM. The organic layers were combined and dried (MgSO4) then concentrated under in 
vacuo. The crude oil was purified by column chromatography (8:2 Hexanes:EtOAc) yielding an 
amber coloured oil (37%, 0.058 g). 1H NMR (CDCl3, 500 MHz, 22 °C): δ 8.54 (d, J = 1.6 Hz,  1H), 
8.50 (d, J = 3.5 Hz, 1H), 7.74 (bs, 1H), 7.28-7.26 (m, 1H), 3.26 (d, J = 7.5 Hz, 2H), 2.41 (dt, J = 
11.9, 5.0 Hz, 1H), 2.22-2.12 (m, 2H), 2.02-1.90 (m, 2H), 1.87-1.77 (m, 1H), 1.69 (bs, 1.5H), 1.51-
1.35 (m, 2H), 0.90 (s, 3H). 13C NMR (CDCl3, 500 MHz, 22 °C): δ 149.70, 148.90, 135.20, 123.77, 
67.89, 53.58, 49.19, 35.39, 33.86, 25.02, 22.81, 20.01. ESI-MS: m/z 231.1 ([M+H]+). 
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2.3.7 C8-6-C8 Diazirine 
 
Theophylline six-carbon linked theophylline was synthesized as previously described. One 
equivalent (0.232 mmol) was then solubilized in 5 mL DMSO under nitrogen. Potassium carbonate 
(6 eq, 1.391) was added to the solution before 3-(2-iodo-ethyl)-3-methyl-3H-diazirine (10 eq, 2.318 
mmol) solubilized in DMSO was added to the reaction flask. The flask was sealed and heated to 
50 °C to react overnight. The following morning, the flask was cooled to room temperature and 10 
mL water was added. The solution was extracted three times with 20 mL DCM. The organic phases 
were combined and dried as much as possible before the addition of 25 mL DCM. The DCM was 
extracted three times with 15 mL water. The water layers were combined and extracted three times 
with 15 mL DCM. The new DCM washes were extracted twice with 15 mL water. Both sets of 
DCM layers were combined and dried over magnesium sulfate and under reduced pressure to 
produce a brown oil and precipitate mixture. Silica column chromatography was completed using 
a 9.75: 0.25 ratio of ethyl acetate to methanol. The product from the column (orange precipitate) 
was finally rinsed with acetone to produce the final product, a white precipitate at a 23% yield. 1H 
NMR (CDCl3, 500 MHz, 22 °C): δ 4.20 (t, J = 15.2 Hz, 2H), 3.57 (s, 3H), 3.40 (s, 3H), 2.74 (t, J 
= 15.5 Hz, 2H), 1.84 (t, J = 15.2 Hz, 2H), 1.81-1.73 (m, 2H), 1.49-1.44 (m, 2H), 1.06 (s, 3H). 13C 
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NMR (CDCl3, 500 MHz, 22 °C): δ 155.1, 153.9, 151.8, 148.7, 106.6, 40.5, 36.5, 29.9, 29.1, 28.1, 
27.9, 26.9, 24.0, 19.8. 
2.4 Isothermal Titration Calorimetry 
Both the protein and the drug were dissolved in phosphate-buffered saline (PBS) (0.01 M 
phosphate buffer, 0.0027 M potassium chloride and 0.137 M sodium chloride, pH 7.4, at 25 °C) to 
the desired concentration. The samples were degassed and then loaded into a NanoITC calorimeter. 
The more concentrated sample was added to the syringe, and the more dilute sample was added to 
the well. The temperature was held at 20 °C, and the well was mixed at 300 rpm. For each 
experiment, twenty aliquots of 2.5 μL of the sample were injected into the well at 250 s intervals 
except for the first injection which was 0.48 μL. NanoAnalyze software was used to process the 
data. 
2.5 Thioflavin T Assay Conditions 
First, 56.25 μL of 2 mg/ml AS and 18.75 μL of PBS at physiological pH (7.4) were pipetted 
into a 0.25 mL microcentrifuge tube to produce a 1.5 mg/mL solution of AS. Next, 3.75 μL of 10 
mM drug or buffer were added to the microcentrifuge tube to obtain 500 μM of the drug in the 
assay. All components were mixed and settled at the bottom of the microcentrifuge tube by flicking 
the tube. The tubes were placed in large vials that could be held by the thermomixer. Some sand 
was added in the vials to fill the space between the tubes and vials to facilitate heat transfer. The 
tubes and sand were held in place by wrapping parafilm around the top of the vials. Each 
experiment was run in triplicate. The vials were added to the thermomixer at 37 °C and 1400 rpm 
for 5 days. Working in the dark, a 26 μM working solution of ThT was made. From each tube, 10 
μL AS mixture was pipetted in triplicate onto a 96-well plate to which 144 μL ThT working 
solution was added. Fluorescence of the wells was measured by excitation at 444 nm and emission 
at 484 nm with a plate reader. The data was treated by first averaging the readings coming from a 
single tube. The resulting averages from tubes of the same drug were compared with the control 
using a t-test assuming equal variances. 
2.6 Photoaffinity Labelling Protocol 
To each quartz tube used in the assay, AS protein was added from a stock solution of 69.15 
μM to the final required concentration of protein. The buffer (TRIS•HCl 20 mM, NaCl 100 mM, 
pH 7.4) was added to dilute AS to the appropriate concentration for labelling. To the control, both 
25 
 
the buffer and DMSO were added for a total of 200 μL solution in the vial and 1% DMSO. To the 
experimental vial, the drug was added to the appropriate final concentration of probe in a 200 μL 
vial with a final concentration of 1% DMSO. The vials were mixed so that all the fluid was at the 
bottom of the vial. Next, the vials were capped and incubated at 37 °C and 220 rpm for 30 minutes. 
Finally, the vials were incubated for a total of 30 minutes under two F20T12/BL/HO UVA lamps 
(National Biological Corp. Beachwood, OH) filtered to remove UVC. The strength of the light 
during this incubation was held at approximately 1500 μW•cm-2 in the UVA range, as measured 
with a UVP UVX-36 sensor (Ultraviolet Products Ltd, Upland, CA). After UVA exposure, the 
samples were transferred to microcentrifuge tubes and stored at -80 °C until analysis. 
2.7 Protein Digestion Protocol 
To each microcentrifuge tube containing 50 µL protein sample dissolved in 100 mM 
ammonium bicarbonate (ABC) buffer, an equal volume of trifluoroethanol (TFE; 50 µL) was 
added. Following this, the samples were placed in a speedvac for 25 minutes in order to remove 
TFE. Cold acetone (1 mL) was then added, samples mixed gently and stored at -80°C for 1 hour. 
Most of the acetone was then removed by centrifugation at 13,000 rpm for 30 minutes, leaving 
behind 50-100 μL solvent. This was repeated once more to remove unwanted material and prepare 
proteins for digestion. After the second time, acetone was removed completely in the speedvac, 
and samples were then reconstituted in 300 μL of 100 mM ABC buffer. Trypsin was added to the 
protein sample in a trypsin/protein ratio of 1:40 and samples were incubated in a shaker at 300 
RPM (Eppendorf Thermomixer, Eppendorf, Mississauga, ON, Canada) overnight at 37°C to digest 
proteins. Trypsin was added again in the morning and incubated in a shaker at 300 RPM for 2 hrs 
at 37°C to complete the protein digestion. The samples were then completely dried and stored at -
80°C until mass spectrometric analysis (LC-MS/MS). The digested protein samples were 
reconstituted in 97:3 water: acetonitrile, containing 0.1% formic acid, to a concentration range of 
1-5 μg/μL prior to LC-MS/MS. 
2.8 LC-MS/MS Analysis 
The mass spectral analyses were performed on an Agilent 6550 iFunnel quadrupole time-
of-flight (QTOF) mass spectrometer equipped with an Agilent 1260 series liquid chromatography 
instrument and an Agilent Chip Cube LC-MS interface (Agilent Technologies Canada Ltd., 
Mississauga, ON, CA). Peptide samples of 1 to 5 µg were injected and chromatographic separation 
was carried out on a high-capacity Agilent HPLC-Chip II: G4240-62030 Polaris-HR-Chip_3C18 
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consisting of a 360 nL enrichment column and a 75 µm × 150 mm analytical column, both packed 
with Polaris C18-A, 180Å, 3 µm stationary phase. Initially, injected samples were loaded onto the 
enrichment column with solvent A (0.1% formic acid in water) at a flow rate of 2.0 µL/min. 
Samples loaded to enrichment column were transferred onto the analytical column and peptides 
were separated with a linear gradient solvent system, consisting of solvent A and solvent B (0.1% 
formic acid in acetonitrile). The linear gradient was 3–25% solvent B for 50 min and then 25–90% 
solvent B for 10 min at a flow rate of 0.3 µL/min. Positive-ion electrospray mass spectral data was 
acquired using a capillary voltage set at 1850 V, the ion fragmentor set at 360 V, and the drying 
gas (nitrogen) set at 225 ºC with a flow rate of 12 L/min. Spectral results were collected over a 
mass range of 250–1700 (mass/charge; m/z) at a scan rate of 8 spectra/s. MS/MS data were 
collected over a range of 100–1700 m/z and a set isolation width of 1.3 atomic mass units. The top 
20 most intense precursor ions for each MS scan were selected for tandem MS with active exclusion 
for 0.25 minutes. Data were analyzed using Agilent MassHunter Qualitative Analysis Software 
(Agilent Technologies Canada Ltd., Mississauga, ON, CA). The BioConfirm molecular feature 
tool was used to extract compounds from the collected data and the incorporation of labeling agent 




RESULTS AND DISCUSSION 
3.1 Synthesis 
3.1.1 Caffeine Diazirine (CD) Probe 
 
Figure 3.1 Synthetic pathway used for diazirine synthesis from 4-hydroxy-2-butanone (far 
left, 1) to create the diazirine linker (far right, 4). 
3-(2-hydroxyethyl)-3-methyl-3H-diazirine (4) was obtained though the route outlined in Figure 
3.1. This begins with 4-hydroxy-2-butanone (1) in which the ketone is converted to an imine (2) 
using ammonia in methanol. Hydroxylamine-O-sulfonic acid is then used to convert the imine to 
into a diaziridine (3). Finally, the diaziridine is converted into a diazirine (4) using a 6% bleach 
solution. The overall yield in three steps is 51% crude yield.  
Initially, the yield for these three steps was a 6% crude yield. A variety of conditions were 
employed to improve the yield of diazirine. For the first step, the length of time, the temperature, 
and the reagents were all changed successively to improve the yield. The oxidizing agent in the 
third step was changed from bleach to potassium hydroxide as well. None of these conditions 
improved the yield.  
The scale of the reaction was increased to 500 mg of starting material in hopes that the reaction 
works better at a larger scale where small impurities (water, etc.) have less influence on the 
reaction. The larger scale reaction improved the yield to 28% crude. The NMR spectrum showed 
the presence of residual solvent from the extraction step; however, attempts to remove residual 
solvent under high vacuum also led to loss of product (11% crude yield after two hours on the high 
vacuum). The NMR spectrum was free of solvent at this point, and the sample was returned to the 
high vacuum to monitor for further product loss. A decrease in the mass of product from 65 mg to 
19 mg occurred over 5 hours, confirming that the diazirine was volatile under high vacuum. To 
confirm that removing the high vacuum step would improve the yield, the reaction was repeated 




One patented literature procedure for the synthesis of 4 made use of the same reagents and 
isolated product via vacuum distillation at 90 °C and 2 mbar. 85 In agreement with the results in 
this work, it only obtained a 3% yield of 4, providing further support for the volatility of 4. The use 
of vacuum distillation should not be ruled out for the isolation of 4 though as it has been used in 
the past for high yielding reactions, but the precise conditions were not listed. 88  
Regarding the sensitivity of the synthesized diazirine compound to ambient light, two samples 
of crude diazirine compound were left out on the bench top for three consecutive days. One sample 
was covered in foil and the other was not. There were no significant changes in NMR spectra 
observed between the two samples over the three days, suggesting little sensitivity to ambient 
visible light. 
 
Figure 3.2 Alternate synthetic conditions for the conversion of the diaziridine to a diazirine. 
The yield corresponds to the yield when converting from the ketone to the final diazirine.  
To further increase the amount of diazirine produced, the same procedure was repeated, 
substituting potassium hydroxide for bleach (Figure 3.2). 89  This reaction only yielded 9% crude 
diazirine. It was concluded that using bleach is more efficient for conversion from diaziridine to 
diazirine, and these conditions were used to move on to the next step.  
When returning to synthesize more diazirine for other monomer compounds, the reaction began 
yielding lower quantities of product again akin to the 9% seen in the reaction with potassium 
hydroxide. The only obvious change made in the preparation of the diazirine was that the drying 
of the diaziridine was not as thorough as it was when originally trying to synthesize the compound. 
Therefore, the amount of time the diaziridine spent on the high vacuum was extended until the 
compound was as dry as possible before the oxidation step. This drying appeared to improve the 
yield to approximately 40% crude product. When repeated another time, the yield had dropped 
back to 9%. Absorption of water by hydroxylamine-O-sulfonic acid (HOSA) was suspected to 
cause this issue. HOSA was dried using diethyl ether and reduced pressure before being used to 
repeat the reaction. There was no observable improvement in the yield. The ammonia in methanol 
solution was replaced following this with a resultant increase to 51% crude yield. Upon further 
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investigation, a second bottle of ammonia in methanol was found in storage which had become 
yellow in colour. It was concluded that alternating between bottles of ammonia in methanol was 
the cause of the changes in yields. While this solves the question of why the yield was poor, it also 
calls into question whether the yield from potassium hydroxide was a result of the quality of the 
ammonia in methanol solution or KOH not being as effective as bleach. 
 
Figure 3.3 Conditions for the tosylation of the alcohol diazirine linker (4) to produce the 
tosylated diazirine linker (5). 
The next step in the synthetic scheme, tosylation of the alcohol of the diazirine, used tosyl 
chloride and trimethylamine to covert the alcohol to the tosylate (Figure 3.3). The reaction yielded 
the tosylated diazirine (5) at a 125% crude yield. NMR indicated the major product was the 
tosylated diazirine linker, so the product was used without further purification. Figure 3.4 shows 
the final step in synthesizing the caffeine diazirine photoaffinity label 6. In this step, theophylline 
is dissolved in DMSO with K2CO3 to enable alkylation at the N7 position when the tosylated 
diazirine compound is added, producing 6 at a 49% yield.  
A functional mobile phase to isolate 5 has been developed which may allow for higher yields 
in the alkylation step. Silica gel column flash chromatography was used to purify 5 with 1:1 DCM: 
hexanes as a mobile phase. The yield resulting from the 1:1 DCM:hexanes column was 75%. It 
should be noted that the use of ethyl acetate in place of DCM to isolate 5 results in coelution of 




Figure 3.4 Conditions for alkylation of theophylline by the tosylated diazirine (5) to produce 
the caffeine diazirine probe (6). 
3.1.2 1-aminoindan Diazirine (AD) Probe 
Synthesis of the 1-aminoindan diazirine probe using the same tosylated linker and 
potassium carbonate conditions from the alkylation of theophylline was unsuccessful. Similarly, 
alkylation utilizing the tosylated linker with potassium carbonate and THF at 50 °C substituted for 
DIPEA and acetonitrile at 45 °C (Figure 3.5) also did not produce the desired product.  
 
Figure 3.5 Conditions for the second attempt at the synthesis of 1-aminoindan diazirine 
probe. 
At this point, the leaving group was hypothesized to be the issue, as our lab had determined 
that different leaving groups were required in the functionalization of caffeine, nicotine, and 1-
aminoindan (O. Aigbogun, personal communication). Consequently, the preparation of 
halogenated linkers was proposed instead of tosylated linkers. To do so, the crude tosylated 
diazirine 5 was converted to a brominated diazirine 7 (Figure 3.6) via reflux of 5 with lithium 
bromide in anhydrous THF. The NMR of the crude product was an unidentifiable crude mixture. 
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To remove some of the impurities from the reaction, 5 was purified before repeating the 
bromination. The resulting NMR from the repeated reaction was modestly cleaner than its 
predecessor, allowing identification of the signals corresponding to 7. Column chromatography 
was not successful at isolating the compound of interest in any subsequent attempts, so the crude 
brominated linker was used in the alkylation step without further purification. The conditions for 
the alkylation with the brominated linker were the same as used in figure 3.4. Unfortunately, the 
reaction was unsuccessful again. 
 
Figure 3.6 Conditions for bromination of the tosylated diazirine linker (left, 5) to form the 
brominated diazirine (right, 7). 
In response to the previous failure to alkylate 1-aminoindan, iodination of the linker was 
proposed. Iodination has been reported as problematic to reproduce. 93 However, careful selection 
of solvents has improved this, with speculation that volatility of 8 may be a contributing factor. 81  
Iodination of 4 uses iodine, triphenylphosphine, and imidazole to perform an Appel-like reaction 
in anhydrous dichloromethane over four hours (Figure 3.7). The reaction is purified by flash 
column chromatography using a 10:1, hexanes: diethyl ether mobile phase resulting in a 46 % yield 
of 8.  The low yield of this reaction is thought to be a result of either the column chromatography 
conditions being suboptimal or the compound being too volatile during the removal of solvent. 
Unfortunately, experimentation was never performed to confirm this observation, so it is possible 
the yield may have been affected by other mechanisms such as the generation of iodine radicals 




Figure 3.7 Conditions for the conversion of the diazirine linker an alcohol (left, 4) directly 
to the iodinated diazirine linker (right, 8). 
  Alkylation was repeated with similar conditions to figure 3.5. 8 was used to alkylate 1-
aminoindan with DIPEA in acetonitrile overnight (Figure 3.8). Flash column chromatography was 
used to purify 9 using a 8:2 hexanes: ethyl acetate mobile phase for a 42% yield.  
 
Figure 3.8 Alkylation of 1-aminoindan with 8 using DIPEA, ACN and heat to produce the 
1-aminoindan probe (right, 9).  
3.1.3 Nicotine Diazirine (ND) Probe 
 The nicotine-diazirine probe was synthesized easily using a similar procedure as was used 
for 1-aminoindan. Iodinated diazirine 8 was produced as described previously before being 
combined with nornicotine and DIPEA to produce 10 (Figure 3.9). Flash column chromatography 




Figure 3.9 Alkylation of nornicotine using 8 to produce the nicotine diazirine probe (right, 
10). 
3.1.4 C8-6-C8 Diazirine Probe (C2D2) 
Alkylation of 1-aminoindan and nornicotine were more responsive to the iodinated 
diazirine linker (8), and the original synthetic pathway used iodomethane to produce C8-6-C8.
 10 
For these reasons, theophylline six carbon linked theophylline (11) was alkylated at the N7 position 
with ten equivalents of 8 and six equivalents of potassium carbonate in DMSO (Figure 3.10). The 
product, C2D2 (12), was purified by column chromatography after extraction with a 9.75:0.25 ethyl 
acetate: methanol mobile phase. Compound 12 was originally isolated at a 43% yield, but the 
product was tinted orange and NMR had a peak at 1.22 ppm that did not correspond to the 
compound. In the original synthesis of C8-6-C8, the final step is to wash the product with acetone 
following alkylation. 10 As column chromatography was not enough for purification of 12, a rinse 
of the product with acetone was proposed for this reaction as well. Fortunately, C2D2 was also 
insoluble in acetone while the impurity appeared to be soluble. 12 was rinsed with acetone, which 
removed the orange colour as well as decreasing the peak height of the NMR impurity at 1.22 ppm. 




Figure 3.10 Alkylation of theophylline six-carbon linked theophylline (top left, 11) using 
potassium carbonate, DMSO, and heat to produce C2D2 (12). 
3.1.5 C8-6-I Diazirine Probe 
 The initial idea for the synthesis of the C8-6-I diazirine probe was to alkylate both the N7 
position and the amine of the 1-aminoindan simultaneously. In order to accomplish this, the 
theophylline six-carbon linked 1-aminoindan would have to react with the iodinated diazirine 8 in 
the presence of DIPEA.  Before doing so, the ability of theophylline to react with 8 was uncertain 
when using DIPEA as a base, therefore a reaction was run doing just that (Figure 3.11). The 




Figure 3.11 Alkylation of theophylline (left) using DIPEA as a base for alkylation of the N7 
position to make the caffeine diazirine probe (right, 6). 
 To begin synthesis of the bifunctional probe, boc-protected theophylline six-carbon linked 
1-aminoindan was synthesized by O. Aigbogun as described previously. 10 The molecule was first 
deprotected using an excess of 4 M HCl in dioxane and anhydrous dichloromethane as solvent. 
The reaction ran overnight with stirring at room temperature. The reaction was quenched by adding 
saturated NaHCO3 to the flask and the mixture was extracted three times with DCM. Column 
chromatography using an 8:2 ethyl acetate: methanol mobile phase obtained deprotected 
theophylline six-carbon linked 1-aminoindan (13) at a 68% yield.  
 The resulting compound (13) was used in combination with 8 (13.5 equivalents) and DIPEA 
(3 equivalents) in tetrahydrofuran at 50 °C overnight (Figure 3.12). New spots appeared on thin 
layer chromatography monitoring of the reaction, but when the spots were subjected to TLC-MS, 
none of them corresponded to masses indicative of either mono- or di-alkylated T-6-I (14). 
Unfortunately, the focus had to be shifted to completing ThT analyses and photoaffinity labelling, 
as such continued attempts at alkylation of 13 were ceased. Substitution of DIPEA with potassium 




Figure 3.12 Conditions used for the attempted alkylation of theophylline six-carbon linked 
1-aminoindan (13) when attempting to produce the doubly alkylated C8-6-I diazirine (14).  
3.2 Isothermal Titration Calorimetry 
 The goal of using ITC was to determine the binding affinity of all compounds to AS, both 
with and without the diazirine groups, to compare the diazirine linker’s effects on binding affinity. 
Unfortunately, we were unable to collect any usable data. The following describes my attempts at 
ITC data collection.  
 Seven key experiments were run prior to termination of ITC experiments, listed in table 1. 
In these experiments, modifications were made as follows.  
1. The drug may be placed in the syringe of the ITC instrument and AS placed in the well, i.e. the 
drug is then injected into the well (i.e. trial #1, #4 in table 3.1).  
2. The concentration of drug being injected into the protein can be increased (trial #2, #7 table 3.1). 
This would be attempted if experimental approach 1 does not result in saturation of binding sites. 
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3. AS is placed in the syringe of the ITC instrument and drug placed in the well, i.e. the AS is 
injected into the well. (trial #3, #5, #6 table 3.1).   
4. The solvents used in dilution of both the protein and the drug are identical, i.e. NaOH was not 
used to solubilize AS prior to dilution as it was not being used to solubilize the drug prior to its 
dilution (trial #7 table 3.1). 
First, trial #1 from table 3.1 was completed along with its corresponding control. The result 
of subtracting the control data from the experimental data is shown in Figure 3.13 which suggested 
that the titration of drug into protein was not able to saturate all potential binding sites to produce 
a sigmoidal curve. Therefore, trial #2 made use of a higher concentration of drug (table 3.1). The 
results (data not shown) were the same as for trial #1, indicating that there may be an issue other 
than the inability to saturate binding sites. 
Table 3.1 Key ITC experiments run. 
 
Trial # Syringe Syringe [ ]Well Well [ ] Notes
1 6 50 μM AS 5 μM See figure 3.13 for data
2 6 200 μM AS 5 μM Data similar to figure 3.13
3 AS 50 μM 6 5 μM See figure 3.14 for data
4 Caffeine 50 μM AS 5 μM See figure 3.15
5 AS 50 μM Caffeine 5 μM See figure 3.16
6 AS 50 μM 6 5 μM Data similar to figure 3.16




Figure 3.13 Processed data for 50 μM of 6 into 5 μM AS is inconsistent and does not 
produce the desired curve.  
 Following this, trial #3 from table 3.1 was performed. The resulting graph has an apparent 
sigmoidal shape (Figure 3.14), following subtraction of the control. The Kd was comparable to 
previously reported data for caffeine (Kd = 1.31x10
-6 M), although the number of bindings sites 
was 1 and not 2. 10    
 




 Next, trial #4 from table 3.1 was completed, injecting caffeine into AS. In the literature, 
caffeine was titrated into AS, so this was the procedure used to produce Figure 3.15. 10 However, 
the data was comparable to the data from Figure 3.13 for 6, rather than what had been expected.  
 
Figure 3.15 Trial #4: Processed ITC data for 50 μM of caffeine into 5 μM AS. 
 Given that interchanging the location of the protein and the drug had worked well in the 
case of 6, this was applied to the caffeine-AS titration (trial #5 table 3.1). In addition to this, titration 
of AS into caffeine-diazirine was repeated again to confirm the results of the first titration (trial #6 
table 3.1). Unfortunately, trial #5 from table 3.1 resulted in a horizontal linear line as seen in Figure 
3.16, with trial #6 having similar results (data not shown). The difference in results between trial 
#3 and trial #5 led to the hypothesis that there may have been buffer mismatch in trial #3 (AS 
injected into compound 6, Figure 3.14) between the control and the experimental runs. Whereas 
the control and experimental runs were prepared and completed on the same day and in the same 
way for trial #5, this was not the case for trial #3. The control for trial #3 was completed previously 
(several months prior) and it is unknown if their preparation of the AS stock made use of 1 mM 
NaOH initially to solubilize the protein before its dilution (refer to the ThT experimental section 
for further information on the use of 1 mM NaOH with AS) or if the concentration of NaOH may 
have varied in previous work. Therefore, it is possible that the changes in heat seen in Figure 3.14 




Figure 3.16 Trial #5: Processed ITC data for 50 μM of AS into 5 μM compound 6 (caffeine-
diazirine). 
 To test the most recent hypothesis, trial #7 from table 3.1 was performed which eliminated 
the use of other solvents in the preparation and dilution of AS (i.e. 1 mM NaOH). Again, the data 
from this final experiment was a horizontal, linear line (data not shown) as observed for trial #5 
(Figure 3.16), indicating that buffer mismatch likely produced the angled linear line from earlier 
experiments (trials # 1 and #4, Figures 3.13 and 3.15 respectively). This is reasonable because there 
would have been a minimal amount of NaOH in the well containing AS for the experimental run 
in the samples for trials #1 and #4, but NaOH would not have been present in the control. 
Unfortunately, these results also indicate that the interaction between the drug and AS is either not 
occurring or not observable through ITC.  
Previous work has demonstrated binding of AS to caffeine though ITC. 10  However, the 
studies performed herein have isolated a potential issue that may have caused confusion in previous 
work. Generally, the literature recommends the use of NaOH for the storage of proteins used in 
ThT assays, and AS has been prepared in this way as well. 12,94  NaOH was used for storage of AS 
in early work in this study which led to buffer mismatch in some ITC runs. This work was based 
upon work done by others within the same lab, meaning that NaOH may have been used in previous 
ITC studies. There is no way of knowing when the use of sodium hydroxide was adopted; however, 
this may have contributed to the confusing ITC results in the past.10 Whether these issues can be 
resolved with the current set up is unknown, however it may be useful to investigate alternative 
methods of measuring ligand-AS binding.  
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3.3 Thioflavin T Assay 
  ThT assays, commonly used to observe the effects drugs have on aggregation of proteins 
with beta sheet character, were chosen to observe for the effect that the drugs have on AS 
aggregation.  
3.3.1 Development of a Time-Course ThT Method 
The original ThT assay protocol (J. Garcias, personal communication) employed in this 
work was one that was developed to monitor AS aggregation over time. This approach was taken 
as there was interest in developing an assay which monitored the changes in fibrillation over time 
in a quick and reproducible manner. This meant the ideal protocol would be finished in a single 
workday. The other purpose in performing the assay over time was to reduce the amount of protein 
over the course of this work, consequently saving on cost. Also due to the cost of AS, AS was not 
manipulated as a variable. However, the initial concentration of AS chosen for the assay was based 
upon correspondence with other researchers in the field of PD who have made use of the ThT assay 
in the past (M. J. Daniels, personal communication). 
The assay initially took place by aggregating AS in a 96-well plate with a cover and a small 
polystyrene bead. The plate was then heated and shaken at 300 rpm over the course of seven hours 
to test the effects of a drug. Readings were to be done hourly to obtain the data. Otherwise, the 
experimental conditions are listed in table 3.2, along with all subsequent time-course ThT 















Table 3.2 Experiments run to develop a time-course ThT method. AS concentration and ThT 
concentration refer to the stock concentration for each (50 μL of each was added to the wells). The 
heparin stock concentration was 75 μg/mL for experiments 1-4 and 1 mg/mL for 5 onward.  
 
 Optimization of the experiments in this assay was extensive. Initial experiments carried out 
by me (Figure 3.17) did not result in aggregation as compared to previous data (J. Garcias, personal 
communication). Given the ability of the compounds in the study to rescue yeast cell growth in a 
PD model, the protocol called for the drug of interest to be added at the 5-hour time point 




0 to 200 




0 to 200 
μM 2 mg/mL NaOH 40 μM 2X PBS 7 No 30 7 Drug was added at 5h




0 to 100 
μM 2 mg/mL NaOH 40 μM 2X PBS 7 No 30 24 3.17
Drug was added at 5h; 100 
μM was repeated with 7 μL 
from 1 mg/mL heparin
5 None N/A 2 mg/mL NaOH 40 μM 2X PBS 0 to 20 No 30 22 3.18
6 None N/A 2 mg/mL NaOH 40 μM 2X PBS 0 to 20 No 30 22
Equimolar HCl to NaOH 
added
7 None N/A 2 mg/mL NaOH 40 μM 2X PBS 20 No 30 20 3.20 Repeated in quadruplet
8 None N/A 2 mg/mL NaOH 40 μM 2X PBS 20 No 30 24
6.3 μL of 20 mM EDTA 
added
9 None N/A 2 mg/mL NaOH 40 μM 2X PBS 20 No 30 24
Equimolar HCl to NaOH 
added and mixed before 
pipetting into wells
10 None N/A 2 mg/mL NaOH 40 μM 2X PBS 20 No 30 24 Beads rinsed with water
11 None N/A 2 mg/mL 1X PBS 40 μM 1X PBS 0 to 20 No 37 24 3.19
12 None N/A 2 mg/mL 1X PBS 40 μM 1X PBS 15 No 37 7 3.21
13 None N/A 2 mg/mL 1X PBS 40 μM 1X PBS 15 Yes 37 7 3.22
14 1-aminoindan
0 to 200 
μM 2 mg/mL 1X PBS 40 μM 1X PBS 15 Yes 37 7 3.23
15 1-aminoindan
0 to 200 
μM 2 mg/mL 1X PBS 40 μM 1X PBS 0 Yes 37 49 3.24
16 cNDGA
0 to 200 
μM 2 mg/mL 1X PBS 40 μM 1X PBS 5 Yes 37 24
17 1-aminoindan
0 to 200 
μM 2 mg/mL 1X PBS 40 μM 1X PBS 5 Yes 37 24 3.27
18 1-aminoindan
0 to 200 
μM 2 mg/mL 1X PBS 40 μM 1X PBS 5 No 37 24 3.28
19 1-aminoindan
0 to 200 
μM 2 mg/mL 1X PBS 40 μM 1X PBS 2 Yes 37 48 3.29
20 1-aminoindan
0 to 600 
μM 2 mg/mL 1X PBS 40 μM 1X PBS 5 Yes 37 24 3.30
21 cNDGA
0 to 500 
μM 2 mg/mL 1X PBS 40 μM 1X PBS 5 Yes 37 24 3.26
22 None N/A None N/A 40 μM 1X PBS 5 Yes 37 24
Equivalent volume PBS 
added (50 μL) to AS 
removed
23 None N/A None N/A 40 μM 1X PBS 5 No 37 24
Equivalent volume PBS 
added (50 μL) to AS 
removed
24 C8-6-I 
0 to 500 
μM 2 mg/mL 1X PBS 40 μM 1X PBS 5 Yes 37 24 3.32
25 C8-6-N
0 to 500 
μM 2 mg/mL 1X PBS 40 μM 1X PBS 5 Yes 37 24 3.33
26 None N/A 2 mg/mL 1X PBS 40 μM 1X PBS 0 No 37 96 3.34
27 cNDGA
100, 500 
μM 2 mg/mL 1X PBS 40 μM 1X PBS 0 No 37 96 3.34
28 C8-6-I 
100, 500 
μM 2 mg/mL 1X PBS 40 μM 1X PBS 0 No 37 96 3.34
29 C8-6-N
100, 500 
μM 2 mg/mL 1X PBS 40 μM 1X PBS 0 No 37 96 3.34
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(experiments 2 and 4 from table 3.2). 10  Due to the assay failing, this was abandoned early in the 
development of the protocols where drugs were being tested. 
 
Figure 3.17 There is more aggregation of AS with more heparin. Graph shows changes in ThT 
fluorescence in the presence of varying quantities of fluorinated caffeine derivative. The * denotes 
the well using 100 μM fluorinated caffeine with a final heparin concentration of 64 μg/mL, as 
opposed to the final concentration 5 μg/mL heparin in the other wells. Fluorescence measured with 
excitation/ emission 444/ 484 nm. 
 In an effort to improve the assay, several changes were made that had little to no impact on 
the assay. First, HCl was used in two experiments to try to resolve issues with aggregation 
(experiments #6 and #9 from table 3.2). The aggregation did not improve because of these 
experiments though (data not shown). Second, EDTA was used in another attempt at improving 
the assay (experiment #8 from table 3.2). Again, there was no resulting improvement in aggregation 
with this experimental manipulation (data not shown). Third, the plastic beads used in the study 
were rinsed with buffer (experiment #10 from table 3.2). Not surprisingly, there was no 
improvement in the assay with this modification as well (data not shown).  
 Both the temperature and the use of NaOH were altered simultaneously as part of 
optimization (experiment #11 from table 3.2). The time needed to reach maximal aggregation 
improved as demonstrated by the change from figure 3.18 to figure 3.19. Due to the simultaneous 
modifications, it is impossible to say to what extent either change helped or if one of the two 
































Figure 3.18 Using 20 μL of 1 mg/mL gives the fastest aggregation from varying amounts of 
heparin. Graph shows changes in ThT fluorescence in response to increasing volumes of heparin 
added to the assay wells. The legend corresponds to the number of μL of 1 mg/mL heparin used in 
each well. Fluorescence measured with excitation/ emission 444/ 484 nm. 
 
Figure 3.19 Re-optimization of assay with new conditions suggests that 15 μL of 1 mg/mL 
heparin should be used instead of 20 μL of 1 mg/mL heparin. Graph shows changes in ThT 
fluorescence in response to varying quantities of 1 mg/mL heparin under new conditions of 37 °C 
and PBS. The legend is the number of μL of 1 mg/mL heparin used in each well. Fluorescence 



























































 The change in temperature and buffer also improved another aspect of the assay. 
Reproducibility between wells improved when the conditions in figure 3.20 are changed to those 
from figure 3.21. However, these results are not entirely comparable as the quantity of heparin is 
increased in figure 3.20.   
 
Figure 3.20 Variation is significantly different between identically prepared wells. Graph 
shows changes in ThT fluorescence over time in four wells prepared the same way with 20 μL of 
1 mg/mL heparin. Each symbol (◼, ◆, ▲, ) represents a different well. Fluorescence measured 
with excitation/ emission 444/ 484 nm. 
 










































changes in ThT fluorescence in response to new assay conditions with 15 μL of 1 mg/mL heparin 
repeated in quadruplet. Each symbol (◼, ◆, ▲, ) represents a different well. Fluorescence 
measured with excitation/ emission 444/ 484 nm. 
 Spiking the wells with protein was the first of the two variables to improve the assay the 
most. This involved pipetting a small volume of some previously aggregated protein into the 
experimental wells. There was a corresponding improvement in reproducibility during the period 
in which the fibrils were growing as seen when comparing figures 3.21 to figure 3.22. 
 
Figure 3.22 The addition of AS aggregate spike improves reproducibility. Graph shows 
changes in ThT fluorescence when previously aggregated protein is added along with the new 
conditions which include 15 μL of 1 mg/mL heparin repeated in quadruplet. Each symbol (◼, ◆, 
▲, ) represents a different well. Fluorescence measured with excitation/ emission 444/ 484 nm. 
Heparin was the second of the two most effective variables at improving the assay. Heparin 
sped up the rate of aggregation and increased the reproducibility as well. The increase in 
aggregation rate can be visualized in figure 3.19. Improvement to reproducibility was observed in 
























Figure 3.23 Little observable changes in response to the use of 1-aminoindan in the newly 
designed seven-hour long ThT assay. Graph shows changes in ThT fluorescence in response to 
the addition of 1-aminoindan. The legend is the concentration of 1-aminoindan in μM used in each 
well. Fluorescence measured with excitation/ emission 444/ 484 nm. 
 
Figure 3.24 The removal of heparin from the seven-hour long ThT assay with 1-aminoindan 
does not result in dose-dependent effects for 1-aminoindan. Graph shows changes in ThT 
fluorescence in response to the aforementioned conditions. The legend is the concentration of 1-





























































 Negative controls were run to confirm there was no significant background fluorescence in 
experiments #22 and #23 from table 3.2. Fluorescence was not significant in either control (data 
not shown).  
 Also, a positive control was used for the assay, cyclized nordihydroguaiaretic acid 
(cNDGA) (Figure 3.25). cNDGA is known for its ability to inhibit the aggregation of AS in ThT 
assays. 95 cNDGA would result consistently in a dose-dependent reduction of fibril growth in the 
assays in which it was used. Figure 3.26 best depicts the results; however, cNDGA consistently 
worked in a variety of other conditions (data not shown). 
 
Figure 3.25 Chemical structure of cyclized nordihydroguaiaretic acid (cNDGA). 
 
Figure 3.26 Dose-dependent changes in response to cNDGA assay repeated with an additional 
well at 500 μM cNDGA. Graph shows changes in ThT fluorescence with the same conditions as 






























in this assay at each time point and averaged. The legend is the concentration of cNDGA in μM 
used in each well. Fluorescence detected with excitation/ emission 444/ 484 nm.  
 
 Unlike cNDGA, 1-aminoindan did not produce dose-dependent changes in AS aggregation 
in the same conditions as figure 3.26 (Figure 3.27). The lack of dose-dependent changes was 
consistent in a variety of other conditions (Figures 3.28-3.30). For example, figure 3.29 shows that 
100 μM 1-aminoindan has the most aggregation and 200 μM has the least. The remaining quantities 
of 1-aminoindan (5, 10, 50 μM) and the control were arbitrarily positioned in between, whereas the 
data for cNDGA (Figure 3.26) is in the following order: the control, 5 and 10 μM, 50 μM, 100 μM, 
200 μM, and 500 μM.    
 
Figure 3.27 No dose-dependent response to the use of 1-aminoindan in the newly modified 
assay conditions. Graph shows changes in ThT fluorescence resulting from the use of 1-
aminoindan, spike, and 5 μL of 1 mg/ml heparin. The legend is the concentration of 1-aminoindan 































Figure 3.28 Removal of the spike from the same conditions as the previous assay does not 
result in an observable dose-dependent response. Graph shows changes in ThT fluorescence in 
response to the use of varying concentrations of 1-aminoindan, no spike, and 5 μL of 1 mg/ml 
heparin. The legend is the concentration of 1-aminoindan in μM used in each well. Fluorescence 
detected by excitation/ emission 444/ 484 nm. 
 
Figure 3.29 The re-introduction of the aggregated protein spike and the reduction of heparin 
from 5 to 2 μL of 1 mg/ml stock does not produce a dose-dependent response to 1-aminoindan. 
Graph shows changes in ThT fluorescence over time in response to the new conditions. The 
readings were repeated three times in this assay at each time point and averaged. The legend is the 
concentration of 1-aminoindan in μM used in each well. Fluorescence detected by excitation/ 





























































Figure 3.30 The return to previous assay conditions with an increase in the maximum 1-
aminoindan concentration used does not produce dose-dependent ThT fluorescence changes. 
The readings were repeated three times in this assay at each time point and averaged. The legend 
is the concentration of 1-aminoindan in μM used in each well. Fluorescence detected with 
excitation/ emission 444/ 484 nm. 
 Early experiments made use of a fluorinated caffeine derivative (table 3.2 experiments 1-
4). Due to its structural similarity to caffeine (Figure 3.31), it was hypothesized to reduce AS 
aggregation, but none was observed with early experimental conditions (Figure 3.17). The caffeine 
derivative was not employed in the final time-based assay conditions, as such no certain conclusion 
is possible. 
 






























 Finally, the compounds C8-6-I and C8-6-N were tested for anti-fibrillogenic activity in the 
finalized conditions. There was no corresponding dose-dependent reduction in fibrils (Figures 3.32 
and 3.33). This was consistent without heparin or a protein spike as well, but under the same 
conditions cNDGA was still effective (Figure 3.34).  
 
Figure 3.32 No dose-dependent response for C8-6-I with the finalized seven-hour long assay 
conditions. Graph shows changes in ThT fluorescence in response to the conditions used. The 
readings were repeated three times in this assay at each time point and averaged. The legend is the 
concentration of C8-6-I in μM used in each well. Fluorescence detected with excitation/ emission 






























Figure 3.33 No dose dependent response for C8-6-N in the finalized assay conditions. Graph 
shows changes in ThT fluorescence in response to the conditions used in the assay. The readings 
were repeated three times in this assay at each time point and averaged. The legend is the 
concentration of C8-6-N in μM used in each well. Fluorescence detected with excitation/ emission 































Figure 3.34 Confirmation of results from previous assays without the use of either heparin 
or a protein spike. No changes observed for C8-6-I or C8-6-N in comparison to the control, but 
the cNDGA positive control still shows changes in fluorescence. Changes in fluorescence for 
different drugs at 100 and 500 μM as well as a control. The control was run in triplicate. The 
experimental wells were not. The y-axis corresponds to the fluorescence in arbitrary units. The x-
axis corresponds to hours. Top left is the control. Top right is the C8-6-I. Bottom left is cNDGA. 
Bottom right is C8-6-N. Fluorescence measured with excitation/ emission 444/ 484 nm. 
It was possible 1-amnioindan might not have had observable effects as the effects resulting 
from the monomer compounds (i.e. 1-aminoindan, nicotine, caffeine) were not as strong as they 
were with the bifunctional compounds (i.e. C8-6-C8, C8-6-I, C8-6-N).
 79  However, the bifunctional 
compounds should have had observable effects in figures 3.32 and 3.33. Thus, it was possible the 
heparin was impairing the ability to observe any apparent changes to fibrillation. Removal of 
heparin did not ameliorate the results in figure 3.34, so the transition was made to a single time-
point method for the ThT assay to retest the most recent observation. This decision was also 
supported by some of the limitations of the time-course ThT assay methodology. 
The first potential limitation of this experimental design was the addition of fibril seeds to 





































in some cases, especially ones which monitor aggregate development over time, although it may 
be a limitation in others as it may remove an essential step in aggregation from the experiment.  
 The use of heparin was the other potential limitation to the time-course assay developed. 
Heparin has been tested for pro-aggregation effects on AS previously. 94,96  This is confirmed again 
in the current work as the addition of heparin results in faster aggregation of AS. Interestingly, an 
increase in final fluorescence values was also observed in accordance with the addition of 
increasing amounts of heparin (Figure 3.19). One possible explanation for this phenomenon is that 
heparin may alter the way AS fibrils form in the assay. Alternatively, heparin may alter the way 
ThT can interact with the developing AS fibrils. Analyzing the cause for this observation was 
beyond the scope of the research question. Therefore, it was not pursued any further. However, 
there is evidence to support the integration of heparin into the fibrils and different fibril morphology 
with heparin. 94 Thus, the use of heparin may be criticized on the basis of producing a ThT assay 
that does not accurately represent PD pathology. Another potential criticism for a heparin-based 
assay is that the effects may only occur in the presence of heparin. Therefore, applying heparin to 
the ThT assay should be considered carefully in future work.  
In summary, the goal of achieving a time-course ThT assay was considered complete due 
to the success with the positive control (Figure 3.26). Unfortunately, 1-aminoindan, C8-6-I, and C8-
6-N did not demonstrate the ability to inhibit AS aggregation with the time-course method. Due to 
the limitations of this time-course method, it was still possible these compounds had an effect, so 
a final change in methodology was the best option to obtain clearer results. 
3.3.2 Development of a Single Time Point ThT Method 
The methodology for the following protocol was followed from the literature. 95 This 
procedure only measured the end point of AS aggregation. Unfortunately, this change meant that 
the assay requires more protein than the time-course assay. This was done with the goal of reducing 
the time required for the assay to take place (M. J. Daniels, personal communication). However, 
the experimental set up was far simpler (i.e. no heparin, spike, or ThT present) and allowed for the 
use of statistics to compare the control to the drug, thereby making it less qualitative and open to 
criticism. The methods section details the full, finalized procedure for the single time point ThT 
method. Switching to the single time point method required some optimization prior to reaching 
the final procedure.  
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Early attempts at completing the single time point method had to be optimized on three 
fronts. The evaporation of solvent was the first problem encountered with the set up. Originally, 
the vials used were 0.5 mL microcentrifuge tubes as these fit into the thermomixer on their own. 
Due to evaporation of solvent in the tube, it was decided to transition to smaller tubes (0.25 mL or 
so) to reduce the surface area. To supplement this modification, parafilm was used to keep the lids 
shut. The parafilm also served a dual purpose as it was used to anchor the smaller microcentrifuge 
tubes into larger vials. 
 Larger vials were required to hold onto the small microcentrifuge tubes as they were not 
capable of staying in the thermomixer on their own otherwise. This led to the second issue 
encountered with the new assay: heat transfer. With the small tube seated in the larger vial, there 
was a large gap between the two. This resulted in slower aggregation for the assay. Therefore, sand 
(Ottawa sand from fisher scientific) was used to resolve the issue. The sand was used to fill the 
space between the two vials, resulting in the aggregation returning to approximately 80% of the 
original value before the transition to the smaller tube.  
 The final modification to the assay was to extend the duration of the assay in order to 
achieve maximum aggregation. As seen in the time-based ThT assay, the growth phase of the fibrils 
could vary significantly between trials (refer to Figure 3.20). This was the same in this assay as 
well. Three controls were run, and their variation was considered statistically significant as per a 
one-way ANOVA (P=0.0017). However, when the assay was extended to five days, there was no 
statistically significant differences between the wells (P-value > 0.05). Thus, a five-day incubation 
time was chosen going forward as it allowed for the assay to reach its end point.  
In terms of establishing a single time point based ThT assay, all three of these conditions 
should be optimized. This work was based upon the work of others, and evidently, there are 
differences in the performance of the assay. Optimization of the assay is recommended prior to 
testing of drugs due to these differences. Furthermore, optimization prior to drug testing would 
save on costs as there will be less protein wasted overall. 
Finally, the drugs of interest were tested in two batches. In the first group, every drug (or 
control) was run in triplicate and then pipetted in triplicate for readings after the five-day incubation 
period (see methods section for a succinct description of assay conditions). The drugs of interest 
in this experiment were caffeine, C8-6-C8, and C2D2. The control wells in this assay were consistent 
(P-value > 0.05) with the data from the optimization phase of assay development. Comparing the 
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drugged vials to the control vials with a t-test assuming equal variance suggests no difference 
between control wells or drug wells (P-value > 0.05). Two controls were run for the single time 
point ThT assay which measured free AS both in the presence and the absence of ThT. Neither of 
these two controls had any significant fluorescence.  
 The same results were obtained with the second set of compounds used in the single time 
point assay. Caffeine-diazirine, nicotine-diazirine, 1-aminoindan diazirine, C8-6-I, 1-aminoindan, 
and (S)-nicotine were not significantly different from the control when comparing with a t-test 
assuming equal variance (P-value > 0.05). Again, the variation between control vials was not 
significant when compared with a one-way ANOVA (P-value > 0.05).  
All drugs of interest, both monomers and bifunctional agents, were previously shown 
capable of rescuing yeast cell growth in a yeast cell model overexpressing AS. 10  This was 
hypothesized to occur though direct interaction with AS protein as ITC demonstrated their ability 
to interact with AS. Unfortunately, the results from the ThT assays support the null hypothesis.  
There was no observed reduction in AS aggregation as shown by ThT in this work, except 
for cNDGA which was the positive control. The results were consistent in a variety of assay 
conditions (i.e. both the time-based and single point ThT assays) for both the positive control and 
the drugs of interest. In contrast to the drugs in this work, cNDGA had been used in previous ThT 
assays. 95 The results herein support the conclusion that the molecules tested do not inhibit AS 
aggregation through a direct mechanism. However, this does not eliminate the possibility of the 
drugs affecting aggregation though alternative cellular pathways that would in turn prevent or 
reduce aggregation. This was even speculated as a possibility in previous work and may be worth 
investigating further in the future. 10  
All the tested compounds had been observed to cause conformational changes to AS when 
analyzed via nanopore. 8,10  It may be that the conformational changes do not affect aggregation but 
rather some other property of AS in yeast cells that is protective. 
In congruence with the results for the monomers and bifunctional agents, all the diazirine 
probes synthesized in the work did not inhibit AS aggregation in the ThT assay. The implication is 
that the addition of the diazirine linker does not affect the lack of activity. However, as there was 
no activity observed for the monomers or bifunctional compounds, it is difficult to say to what 
extent the linker affects the way the molecules interact with AS. 
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3.4 Photoaffinity Labelling Studies 
 After characterizing the compounds of interest, the final step could be taken: photoaffinity 
labelling (PAL). The labelling protocol was decided upon by surveying the literature for similar 
photoaffinity labelling studies. As the purpose of this study is to determine the monomers’ and 
bifunctional compounds’ interaction to AS, PAL will be performed in vitro. Recent in vitro studies 
were used as benchmarks for experimental set up. In vitro studies made use of either buffer or 
water to solubilize protein for labelling. AS protein was lyophilized in TRIS•HCl 20 mM, NaCl 
100 mM, pH 7.4 buffer prior to purchase, so this buffer was chosen for the procedure. Other studies 
have reported using the same buffer with no ill effects. 79,97  DMSO was used in limited amounts to 
solubilize the drug in similar studies, therefore this strategy was adopted whenever possible. 79,95,97  
Concentrations of protein used ranged from 1 μM to 10 μM with the probe generally equimolar or 
in excess to the protein. 97–100  Given the cost of AS, 1 μM was used as a starting point. Also, a high 
probe: protein ratio (10:1) was chosen.  Most studies had an incubation period prior to irradiation 
which averaged to half an hour. 97–99,101  UV exposure for diazirine-based photoaffinity labelling 
was brief. Half an hour was the maximum length of time in such studies. 97–101  Therefore, a 30-
minute incubation period followed by a 30-minute irradiation period were used as starting points 
for labelling experiments. Light intensity from the source was frequently not measured. The few 
studies that did were far stronger (light flux: 5 mW/cm2 and 14 mW/cm2) than what could be 
achieved with the UVA lamp (light flux: 1.5 mW/cm2). 97,101  However, this was acceptable as 
additional experiments at the lower intensity can be used to confirm activation of the diazirine 
probes by UV light. 
3.4.1 PAL and LC-MS Analysis of Intact Protein 
For the first attempt at PAL, the assay made use of a final concentration of 1 μM protein. 
Three controls were run along with the experimental vial. One control had AS but no probe, and it 
was exposed to UV light for the same duration as the experimental vial. The other two controls 
were prepared in the same way as the first two with the exception that they were not exposed to 
UV light. The probe used to test the protocol was the caffeine diazirine probe, added to the mixture 
in a tenfold excess. The duration of UV exposure was 30 minutes. Following UV exposure, the 
buffer was removed and the protein was re-suspended in 100 mM ammonium bicarbonate buffer 
before being subjected to LC-MS. Analysis of the intact protein did not demonstrate any labelling 
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of either the control or experimental vials with the diazirine probe. The protein exposed to UV light 
did not show any notable changes, implying the protein held up without injury under the light used.  
 To pressure the probe to label the protein, the next experiment increased the duration of UV 
light exposure to six hours. Again, another control was prepared with only AS protein present to 
confirm there were no negative effects on the protein related to UV exposure. The protein appeared 
to be intact following mass spectrometric analysis, but again, there was no labelling of the protein.  
 The following PAL experiment modified the ratio of probe and protein. This time, a one-
hundred-fold excess of drug was used (100 μM CD). All other experimental parameters were kept 
consistent as the previous PAL experiment. Once mass spectrometry was performed, no labelling 
of the protein by the caffeine-diazirine was observed with the increase in probe concentration. 
 Given that the strength of the UV light used in PAL experiments in literature was largely 
ignored as a parameter measured, confirmation was desired that the probe was reacting with UV 
light. The following experiment run was two vials of only 100 μM CD in buffer, either exposed or 
not exposed to UV light. When analyzed with HPLC-MS, there was a peak on the DAD which 
corresponded to a compound with a m/z of 253. This peak was not present in the control; therefore, 
it was thought to be the probe that had reacted with water from the solvent, indicating that the probe 
was activated by UV light at the intensity it was applied during all previous experiments. 
Unfortunately, this also indicates that the issue with the labelling lies elsewhere.  
3.4.2 PAL and LC-MS Analysis of Digested Protein 
 As options were limited to optimize the conditions further, the following attempt did not 
make any changes to the protocol. Instead, digestion was performed prior to HPLC-MS so that the 
proteins would be broken down into peptides, and hopefully, this could help with detection of the 
label on the peptides. This approach resulted in observation of a labelled peptide fragment. HPLC-
MS/MS was used to determine the precise location of the labelling. Labelling was observed on the 
tyrosine 39 position of the protein, which is in the N-terminal region of AS. It is interesting to note 
that tyrosine 39 is located in a potential binding region in AS fibrils. 79 This may indicate the 
importance of this region in both aggregated AS and free AS interactions with small molecules. 
 Given the positive results from the previous PAL experiment, there was the desire to 
confirm the results a second time and perhaps even identify additional binding sites. The 
experiment was repeated on two separate days with two sets of modifications. The first 
modification was that the concentration of protein was increased tenfold, maintaining the same 
60 
 
concentration of probe. The second experiment used the changes from the first experiment as well, 
but the length of UV exposure was shortened to 30 minutes. These experiments both yielded 
labelling of tyrosine 39, like the previous labeling study. Two new modifications were identified 
in the six-hour incubation period at amino acids 28 and 136 which correspond to glutamic acid and 
tyrosine, respectively. Unfortunately, the modification to the 136 position was not fully validated 
due to missing ions in the spectra. The 30-minute labelling period was able to identify the 
modification to glutamic acid 28, but it did not identify modification at tyrosine 136. It remains 
possible that tyrosine 136 was labelled, but further optimization would be required such as using 
alternative proteins for digestion. However, it can be stated confidently that glutamic acid was 
labelled. 
 These findings partially support the hypothesis that caffeine binds in both the N- and C-
terminal regions of AS, assuming CD is an appropriate substitute for caffeine. Taking the ThT and 
ITC data into consideration, one must wonder whether the binding events are specific. PAL in the 
presence of both CD and caffeine may be able to allow further insight into the issue.  
 One in silico study supports some of the results from the CD PAL studies.102 This study 
reports potential interactions of caffeine near the tyrosine 39 position, but it does not report 
interactions occurring close to either glutamic acid 28 or tyrosine 136. A major limitation of the in 
silico study was that AS was kept rigid whereas the inherent conformational flexibility is a known 
challenge for modelling AS in silico.103 Second, this PDB file was of micelle bound AS, a form 
which may not accurately mimic the conformation of AS when bound to small molecules. In spite 
of these limitations, it is interesting to note that the proposed N-terminal binding region 
(approximately Lys 32 to Lys 45) and the binding poses shown could place the diazirine adjacent 
to either Glu 28 or Tyr 39.102 
 Following establishment of the PAL protocol, PAL with digestion prior to MS/MS was 
performed with the remaining probes: AD, ND, and C2D2. The labelling step made use of the 30-
minute UV exposure time. Unfortunately, none of the probes labelled AS in the given conditions. 
No labelling from any of these probes was not entirely unexpected due to the difficulties with the 
ThT assay. Another possibility is that once activated the carbenes may preferentially react with 
solvent, other molecules of AD, ND or C2D2. An additional possibility for C2D2, which possesses 
a great deal of conformational flexibility, is an intramolecular reaction due to pi-stacking of the 
caffeine moieties, although there is no evidence that such an interaction predominates in solution. 
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Therefore, these results support the null hypothesis in that they do not bind preferentially to either 
the N- or C terminal domains.  
3.5 Conclusion 
 In summary, diazirine probes were synthesized for caffeine, 1-aminoindan, nicotine, and 
C8-6-C8. Due to time constraints and a global pandemic, synthesis of diazirine probes for C8-6-I 
and C8-6-N was not completed. ITC was unable to demonstrate binding of caffeine and CD to AS. 
ThT assays for caffeine, 1-aminoindan, nicotine, C8-6-C8, C8-6-I, CD, ND, AD, and C2D2 did not 
demonstrate direct AS fibrillization inhibition. PAL with CD identified three potential binding sites 
for caffeine on AS: tyrosine 39, glutamic acid 28, and tyrosine 136. The remaining PAL compounds 
– ND, AD, and C2D2 – did not label AS protein under our experimental conditions.  
 Taken together, the results support the first study hypothesis (The diazirine functionalized 
probes will interact with AS the same way that the drugs they are derived from interact with AS) 
in that the probes and the drugs from which they were designed behave the same way toward AS. 
However, all compounds did not behave in the way in which they were expected, meaning no direct 
anti-fibrillization activity. The PAL data for CD partially supports the second hypothesis (The 
diazirine-functionalized probes will preferentially label the N- and C- terminal regions of AS), but 
the results from ThT and ITC call into question whether the sites are specifically or non-specifically 
labelled. AD, ND, and C2D2 PAL studies do not support the second hypothesis, but due to the 
limited attempts, labelling may still be possible under different conditions.  
3.6 Future work 
 Given the inability to reproduce the results in previous ITC studies, it would be prudent to 
replicate other studies done in the past. Therefore, the replication of yeast studies is proposed in 
future work, assuming this would be feasible for someone with the necessary background.10 This 
could serve two purposes. First, the results from the yeast study could be reconfirmed. Second, the 
yeast cells may serve as a system for in-cell PAL. 
 Again, given the issues faced with the ThT assay, it may be useful to develop an assay or a 
protocol for testing the quality of AS. Perhaps gel electrophoresis or some variation of mass 
spectrometry may be helpful toward verifying the protein is in the correct state prior to its use in 
biological assays and that there are not contaminants that may affect the outcome of those 
biological assays. While it is unlikely that this was a major issue given the success with cNDGA 
positive controls, it may again be prudent nonetheless. 
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 More biological assays may be beneficial toward our understanding of the mechanisms of 
the bifunctional agents and monomers. For instance, gel electrophoresis could be run following 
aggregation to identify changes in aggregation profiles.95 Circular dichroism may also be used to 
identify the secondary structure of the protein aggregates. Even transmission electron microscopy 
may be beneficial toward understanding the changes in aggregation.  
 Many PAL experiments could be performed following this work. First, there could be 
experiments which vary the stoichiometry of AS to probe. This would allow a qualitative measure 
of the strength of interaction between AS and probe. It would also serve to fine tune the ratio for 
future PAL studies with the probes developed in this work.  
Second, PAL should be performed in the presence of the original drugs. Other studies have 
successfully completed PAL competition studies in vitro to identify the sites that are specific for 
the drug versus those that are non-specific. 100   
Third, PAL of AS fibrils could also be performed. This would allow a better comparison 
between the study done by Hsieh et al. and the probes in this work.79 Also, in silico methods could 
be used in comparison to the results from such a study.  
As was previously mentioned, in-cell PAL could be performed. This would require the 
development of new probes capable of click chemistry with terminal alkynes for isolation (Figure 
3.35), and validation of the newly developed probes.69 However, doing so may provide a more 
complete picture of the binding profile of these small molecules, and potentially offer insight into 
the cellular mechanisms of PD. 
 
Figure 3.35 Proposed PAL click chemistry probe for yeast cell studies. 
Fifth, bifunctional probes could be synthesized that contain only one diazirine functional 
group (Figure 3.36). There are two potential benefits from experiments of this variety. First, the 
synthesis may be easier to complete. Second, only one linker would cause fewer alterations to the 
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overall structure of the bifunctional molecules, which may contribute to the lack of protein labelling 
observed. 
Figure 3.36 Proposed single diazirine functionalized probes for AS binding studies. 
 Finally, more work can be done to optimize the labelling with CD, ND, and C2D2. DMSO 
was used to solubilize these compounds as it had been used in previous work with ThT assays.95 
However, DMSO is known to influence protein conformation with proteins other than AS.104,105 
By making use of another solvent to solubilize these compounds for PAL, we may observe 
changes to labelling. Therefore, a control using methanol to solubilize may be useful.   











Figure 4.1 MS/MS spectrum of a representative tryptic peptide (TKEGVLYVGSK). 




Calculated m/z Measured m/z FRAGMENT 
ION 
Calculated m/z Measured m/z 
y
1
 147.1128 147.1121 b
1
 102.0550 84.0530 
y
2
 234.1448 234.1434 b
2
 230.1499 230.1496 
y
3
 291.1663 291.1645 b
3
 359.1925 359.1907 
y
4
 390.2347 390.2320 b
4
 416.2140 416.2082 
y
5
 553.2980 553.2943 b
5
 515.2824 515.2799 
y
6
 666.3821 666.3773 b
6
 628.3665 628.3656 
y
7
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7
 791.4298 791.4260 
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8
 890.4982 890.4927 
y
9
 951.5146 951.5119 b
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y
10
 1079.6095 1079.5991 b
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Figure 4.2 MS/MS spectrum of TKEGVLyVGSK peptide modified at tyrosine (y) amino 
acid with caffeine diazirine. 




Calculated m/z Measured m/z FRAGMENT 
ION 
Calculated m/z Measured m/z 
y
1
 147.1128 147.1097 b1-H2O 84.0444 84.0413 
y
2
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3
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y
4
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5
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y
6
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y
7
 999.5622 999.5399 b7 1025.5415 1025.5385 
y
8
 1056.5837 1056.5679 b8 1124.6099 1124.6053 
y
9
 1185.6262 1185.6213 b9 1181.6313 1181.5929 
y
10
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